<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000234" GROUP_ID="SCHIZ" ID="938999101209381522" MERGED_FROM="" MODIFIED="2010-06-16 13:00:49 +0200" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Could not find the WONG 1993 reference. Looks out of date in style but OK. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-06-16 11:54:21 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0048" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2010-06-16 13:00:49 +0200" MODIFIED_BY="Claire Irving">
<TITLE>Beta-blocker supplementation of standard drug treatment for schizophrenia</TITLE>
<CONTACT MODIFIED="2010-06-16 13:00:49 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="1A1B584582E26AA2019053359C1E58D6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elena</FIRST_NAME><LAST_NAME>Shek</LAST_NAME><EMAIL_1>elenashek@yahoo.co.uk</EMAIL_1><MOBILE_PHONE>+44 7817 202325</MOBILE_PHONE><ADDRESS><ORGANISATION>Institute of Clinical Research India</ORGANISATION><ADDRESS_1>242A, 13th Cross, CMH Road</ADDRESS_1><CITY>Bangalore</CITY><ZIP>560038</ZIP><REGION>Karnataka</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 9886 949707</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-06-16 13:00:49 +0200" MODIFIED_BY="Claire Irving"><PERSON ID="1A1B584582E26AA2019053359C1E58D6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elena</FIRST_NAME><LAST_NAME>Shek</LAST_NAME><EMAIL_1>elenashek@yahoo.co.uk</EMAIL_1><MOBILE_PHONE>+44 7817 202325</MOBILE_PHONE><ADDRESS><ORGANISATION>Institute of Clinical Research India</ORGANISATION><ADDRESS_1>242A, 13th Cross, CMH Road</ADDRESS_1><CITY>Bangalore</CITY><ZIP>560038</ZIP><REGION>Karnataka</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 9886 949707</PHONE_1></ADDRESS></PERSON><PERSON ID="89643780270439433809091102110653" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sabyasachi</FIRST_NAME><LAST_NAME>Bardhan</LAST_NAME><POSITION>Medical writer</POSITION><EMAIL_1>dr_sabya@yahoo.co.in</EMAIL_1><ADDRESS><ORGANISATION>Indegene Lifesysten Pvt Ltd</ORGANISATION><ADDRESS_1>Golf road</ADDRESS_1><CITY>Bangalore</CITY><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+919 480 550 698</PHONE_1></ADDRESS></PERSON><PERSON ID="17146" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maxim</FIRST_NAME><MIDDLE_INITIALS>V</MIDDLE_INITIALS><LAST_NAME>Cheine</LAST_NAME><EMAIL_1>maxim.cheine@hel.fi</EMAIL_1><ADDRESS><ORGANISATION>Aurora Hospital</ORGANISATION><ADDRESS_1>Nordenskiöldinkatu 20</ADDRESS_1><CITY>Helsinki</CITY><ZIP>FIN-00250</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><FAX_1>+358-9-47181316</FAX_1></ADDRESS></PERSON><PERSON ID="1184CDF382E26AA201DC7B3E581B2F6A" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Juha</FIRST_NAME><LAST_NAME>Ahonen</LAST_NAME><EMAIL_1>juha.ahonen@espoo.fi</EMAIL_1><ADDRESS><ORGANISATION/><ADDRESS_1>Piilopolku 3A3</ADDRESS_1><CITY>Espoo</CITY><ZIP>02130</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 98632492</PHONE_1></ADDRESS></PERSON><PERSON ID="16295" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kristian</FIRST_NAME><LAST_NAME>Wahlbeck</LAST_NAME><POSITION>Professor, Head of Unit</POSITION><EMAIL_1>kristian.wahlbeck@thl.fi</EMAIL_1><EMAIL_2>kristian.wahlbeck@helsinki.fi</EMAIL_2><ADDRESS><DEPARTMENT>Mental Health Promotion Unit</DEPARTMENT><ORGANISATION>THL National Institute for Health and Welfare</ORGANISATION><ADDRESS_2>PO Box 220</ADDRESS_2><CITY>Helsinki</CITY><ZIP>FIN-00531</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 20 610 7300</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-06-15 11:50:45 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="5" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="10" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2010-06-16 11:54:21 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-06-16 11:54:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Updated with four new studies included, data added from these studies do not substantially alter the results and conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-06-15 11:51:59 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-05-04 13:53:41 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-05 13:17:08 +0100" MODIFIED_BY="Bethany York">
<DATE DAY="27" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-06-15 11:51:59 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment. No new trial has been found for this updated version. Some trials are removed from awaiting assessment to be excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-03-04 16:48:22 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-03-04 16:48:22 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-03-04 16:46:15 +0000" MODIFIED_BY="[Empty name]">
<NAME>Institute of Clinical Research India, Bangalore</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2010-03-04 16:48:22 +0000" MODIFIED_BY="[Empty name]">
<NAME>School of Health, Cranfield University</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-06-15 16:30:59 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-05-10 21:33:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-01-13 06:59:38 +0000" MODIFIED_BY="[Empty name]">Beta-blocker supplementation of standard drug treatment for people with schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2010-05-10 21:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>The beta-blockers are a group of drugs that have been used as an addition to 'standard' antipsychotic drugs to treat people with schizophrenia. At present there is very limited good evidence to support this practice.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-06-15 10:34:16 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-04-22 05:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>Many people with schizophrenia or similar severe mental disorders do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, amongst them beta-adrenergic receptor antagonists (beta-blockers).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the clinical effects of beta-blockers as an adjunct to antipsychotic medication in schizophrenia or similar severe mental disorders.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-04-22 05:25:15 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (October 2009) and references of all identified studies for further citations. Where necessary we also contacted authors of trials for further information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials comparing beta-blockers with placebo as an adjunct to conventional antipsychotic medication for those with schizophrenia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-06-03 16:34:22 +0100" MODIFIED_BY="[Empty name]">
<P>Data were extracted independently by at least two reviewers. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis, based on a fixed-effect model. If continuous data were included, we analysed these data using weighted mean difference (WMD) with a 95% confidence interval, based on a fixed effect model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-06-15 10:34:16 +0100" MODIFIED_BY="[Empty name]">
<P>In this 2010 update four additional trials were identified, bringing the total number of included studies to nine (total n=282, eight trials were short term, under/or 12 weeks duration). Overall reporting of data was poor, resulting in much information being lost to this review. No data on mental state were possible to include. Data were reported in graphs with no variances. Adding beta-blockers to antipsychotic treatment seems generally acceptable (n=274, 8 RCTs, RR leaving study early at 12 weeks 1.62 CI 0.92 to 2.83). We found no difference in relapse rate between the two treatment groups (n=68, 2 RCTs, RR at 12 weeks 3.12 CI 0.34 to 28.36). There were few reported general adverse events (n=48, 1 RCT, RR at 12 weeks 5.42 CI 0.27 to 107.20). The most frequent specific adverse effect was hypotension or symptoms likely to be related to hypotension (n=274, 8 RCTs, RR at 12 weeks 1.63 CI 0.70 to 3.84).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-05-11 14:04:57 +0100" MODIFIED_BY="[Empty name]">
<P>Existing evidence is limited and dated. Any possible benefit of adjunctive beta-blocker therapy is obscured by poor reporting within the studies. Important data on quality of life, satisfaction, healthy days, and cost are not available. Considering the number of people whose symptoms are only partially responsive to antipsychotic medication, well conducted and reported trials in this area could be justified.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-06-15 16:30:59 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-05-11 15:25:41 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-05-11 15:25:14 +0100" MODIFIED_BY="[Empty name]">
<P>Worldwide more than 25% of people develop one or more mental or behavioural disorders during their entire lifetime (<LINK REF="REF-WHO-2001" TYPE="REFERENCE">WHO 2001</LINK>). Schizophrenia is one such illness, heavily contributing to the numbers of people considered severely mentally ill. The lifetime prevalence of schizophrenia alone is one per cent in the adult population (<LINK REF="REF-Warner-1995" TYPE="REFERENCE">Warner 1995</LINK>). Currently schizophrenia is 26th on the list of diseases ranked according to contribution to overall burden in terms of disability-adjusted life years (DALYs). Its ranking is projected to rise to 20th by the year 2020, with more than 17 million<B> </B>DALYs lost (accounting for 1.25% of overall burden) (<LINK REF="REF-Murray-1996" TYPE="REFERENCE">Murray 1996</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-05-11 15:25:41 +0100" MODIFIED_BY="[Empty name]">
<P>Beta-adrenergic receptor antagonists (beta-blockers or beta-antagonists for short) are commonly used to treat raised blood pressure and other aspects of heart disease. In the field of mental health beta-blockers are used to help decrease symptoms of anxiety and the disordered movements that result from neuroleptic/antipsychotic medication.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-04-21 14:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Beta-blockers exert their action by blocking the activation of certain beta-receptors (receptors for the adrenaline/epinephrine and noradrenaline/norepinephrine neurotransmitters).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-03-02 15:54:48 +0000" MODIFIED_BY="[Empty name]">
<P>Although antipsychotic medication is the treatment-of-choice for schizophrenia, about 20% of people with this illness do not respond satisfactorily to conventional antipsychotics (<LINK REF="REF-Brenner-1990" TYPE="REFERENCE">Brenner 1990</LINK>). Alternative pharmacological treatments for these people include the so-called 'atypical' antipsychotics such as clozapine, risperidone, olanzapine, and sertindole. Different medications have also been used to supplement 'typical' antipsychotics. Examples include lithium, carbamazepine, benzodiazepines and beta-blockers (<LINK REF="REF-Meltzer-1992" TYPE="REFERENCE">Meltzer 1992</LINK>, <LINK REF="REF-Berlant-1987" TYPE="REFERENCE">Berlant 1987</LINK>).</P>
<P>This review substantially updates the previous version of this Cochrane review (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-04-21 15:00:09 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the clinical effects of beta-blocking agents, as additional medication, for those whose schizophrenic illness is currently being treated with antipsychotic drugs.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-06-15 16:30:59 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-06-15 10:55:01 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-06-15 10:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials lasting one week and over. If there was no clear statement about the randomisation, but if authors implied or suggested it, we included such trials provided that demographic characteristics of each arm of the trial were similar. We undertook a sensitivity analysis in such cases.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-03-26 04:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia, adults aged between 18-65 years, diagnosed by any criteria. Trials were subdivided into those dealing with people with illnesses that had been labelled as 'resistant to antipsychotic drug treatments' and studies that did not have this as an entry criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Any beta-blocking drug in conjunction with any antipsychotic drug treatment.<BR/>2. Placebo added to any antipsychotic drug treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-06-15 10:55:01 +0100" MODIFIED_BY="[Empty name]">
<P>All outcomes were grouped by time - short term (up to 12 weeks), medium term (13 to 26 weeks ) and long term (more than 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-06-15 10:55:01 +0100" MODIFIED_BY="[Empty name]">
<P>1. Mental state<BR/>1.1 General symptoms<BR/>1.2 Specific symptoms<BR/>1.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<BR/>1.2.2 Negative symptoms (avolition, poor self-care, blunted affect)<BR/>1.2.3 Mood - depression</P>
<P>2. Global state<BR/>2.1 Leaving the study early (lost to follow up)<BR/>2.2 Relapse (as defined in trial)<BR/>2.3 Compliance with medication</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-06-15 10:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>3. Behaviour<BR/>3.1 General behaviour<BR/>3.2 Specific behaviours (i.e. self-harm, injury to others or property)</P>
<P>4. Adverse effects<BR/>4.1 Death<BR/>4.2 General problems<BR/>4.3 Specific problems</P>
<P>5. Service use<BR/>5.1 Hospitalisation: Admitted to hospital across time<BR/>5.2 Hospitalisation: Number of admissions across time<BR/>5.3 Use of services outside of mental health provision (i.e. emergency services)</P>
<P>6. Social functioning<BR/>6.1 Imprisonment (i.e. police contacts &amp; arrests)<BR/>6.2 Employment status (number unemployed at end of study)<BR/>6.3 Accommodation status (number homeless or not living independently during or at the end of the study, mean days homeless and mean days in sable accommodation per month in study)<BR/>6.4 Alcohol use<BR/>6.5 Illicit drug use</P>
<P>7. Quality of life<BR/>7.1 Not improved<BR/>7.2 Improved<BR/>7.3 Patient satisfaction<BR/>7.4 Carer satisfaction</P>
<P>8. Economic<BR/>8.1 Costs of psychiatric hospital care<BR/>8.2 Costs of health care (including all medical and psychiatric care and the costs of case management but excluding accommodation other than hospital care)<BR/>8.3 Costs of all care (including costs of accommodation and subtracting benefits (such as earnings) where these are known)</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-05-11 14:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. We searched the Cochrane Schizophrenia Group Trials Register (October 2009). This register is compiled by systematic searches of major databases like CINAHL, EMBASE, MEDLINE, PsycINFO as well as hand searches and conference proceedings (see <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>).</P>
<P>2. For search methods of earlier versions of this review (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>) please see appendix (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-05-11 10:06:39 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Schizophrenia Group Trial Register (October 2009) was searched using the phrase:</P>
<P>[(*acebutolol* OR *alprenolol* OR *amosulalol* OR *arotinolol* OR *atenolol* OR *befunolol* OR *betaxolol* OR *beta blocker* OR *beta-blocker* OR *bevantolol* OR *bisoprolol* OR *bopindolol* OR *bromoacetylalprenololmenthane* OR *bucindolol* OR *bufuralol* OR *bupranolol* OR *butoxamine* OR *carazolol* OR *carteolol* OR *carvedilol* OR *celiprolol* OR *CGP 12177* OR *CGP 20712a* OR *cyanopindolol* OR *dihydroalprenolol* OR *epanolol* OR *esmolol* OR *exaprolol* OR *flestolol* OR *hexadecyl* OR *hydroxypropafenone* OR *icatibant* OR *ICI 118551* OR *ICI 89406* OR *indenolol* OR *iodocyanopindolol* OR *iodopindolol* OR *IPS 339* OR *K 351* OR *labetalol* OR *landiolol* OR *levobunolol* OR *medroxalol* OR *mepindolol* OR *metipranolol* OR *metoprolol* OR *nadolol* OR *nebivolol* OR *oxprenolol* OR *penbutolol* OR *pindolol* OR *practolol* OR *prizidilol* OR *propranolol* OR *sotalol* OR *SR 59230a* OR *talinolol* OR *tertatolol* OR *tilisolol* OR *timolol* OR *tobanum* ) in title, abstract or index terms of REFERENCE and interventions of STUDY]</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-05-11 14:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. References<BR/>Should an included or excluded study suggest that another study was of relevance, the reference was identified and the full text acquired.</P>
<P>2. Personal contact<BR/>Where required for additional data, we contacted authors of trials for this information. We did not systematically contact all authors for additional papers. We contacted relevant pharmaceutical companies and drug approval agencies for additional information.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-06-15 16:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>For previous versions of this section - used in the original review (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>) please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>
</P>
<STUDY_SELECTION MODIFIED="2010-06-03 18:01:50 +0100" MODIFIED_BY="[Empty name]">
<P>For the 2010 update reviewers ES and SB independently inspected all abstracts of studies identified by the searches and identified potentially relevant reports. Where disagreement occurred this was resolved by discussion, or where there was still doubt, the full article was acquired for further inspection. The full articles of relevant reports were acquired for reassessment and carefully inspected for a final decision on inclusion (see <LINK TAG="SELECTION_CRITERIA" TYPE="SECTION">Criteria for considering studies for this review</LINK>). Once the full articles were obtained, authors ES and SB inspected all full reports and independently decided whether they met inclusion criteria. Reviewers ES and SB were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose and if it was impossible to decide, these studies were added to those awaiting assessment and the authors of the papers contacted for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-06-15 16:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>Data were extracted onto standard, simple forms. Authors independently extracted data from included studies. Again, any disagreement was discussed, decisions documented and, if necessary, authors of studies were contacted for clarification. With remaining problems Clive Adams (Co-ordinaitng Editor, Cochrane Schizophrenia Group) again helped clarify issues and those final decisions were documented. Data presented only in graphs and figures were extracted whenever possible, but were included only if all review authors independently came to the same results. Attempts were made to contact authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. Where possible, we extracted data relevant to each component centre of multi-centre studies separately.</P>
<P>1. Scale-derived data<BR/>We included continuous data from rating scales only if:<BR/>a) the psychometric properties of the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b) the measuring instrument was not written or modified by one of the trialists for that particular trial; and<BR/>c) the measuring instrument was either (i) a self-report or (ii) completed by an independent rater or relative (not the therapist).</P>
<P>2. Endpoint versus change data<BR/>We preferred to use scale endpoint data, which typically cannot have negative values and is easier to interpret from a clinical point of view. Change data are often not ordinal and are very problematic to interpret. However, if endpoint data were unavailable we used change data.</P>
<P>3. Skewed data<BR/>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); c) if a scale starts from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above will be modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. When continuous data are presented on a scale which includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. Skewed data from studies of less than 200 participants were entered in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large and were entered into syntheses.</P>
<P>4. Common measure<BR/>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
<P>5. Conversion of continuous to binary<BR/>Where possible, efforts were made to convert outcome measures to dichotomous data. This could be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>, <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>6. Direction of graphs<BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for beta-blocker as an adjunct therapy.</P>
<P>7. Summary of findings table<BR/>We anticipate including the following long-term main outcomes in a Summary of Findings table:</P>
<P>1. Mental state<BR/>1.1 General symptoms<BR/>1.2 Specific symptoms<BR/>1.2.1 Positive symptoms (delusions, hallucinations, disordered thinking)<BR/>1.2.2 Negative symptoms (avolition, poor self-care, blunted affect)<BR/>1.2.3 Mood - depression</P>
<P>2. Global state<BR/>2.1 Leaving the study early (lost to follow up)<BR/>2.2 Relapse (as defined in trial)<BR/>2.3 Not improved to a clinically meaningful extent (as defined in trial)<BR/>2.4 Compliance with medication</P>
<P>3. Behaviour<BR/>3.1 General behaviour<BR/>3.2 Specific behaviours (i.e. self-harm; injury to others or property)</P>
<P>4. Adverse effects<BR/>4.1 Death<BR/>4.2 General problems<BR/>4.3 Specific problems</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-05-10 16:18:27 +0100" MODIFIED_BY="[Empty name]">
<P>Again working independently, authors ES, SB and CP<B> </B>assessed risk of bias using the tool described in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would have excluded studies where allocation was clearly not concealed.</P>
<P>Trials with high risk of bias (defined as at least three out of six domains categorised as 'No') were removed from the 'included' category. If the raters disagreed, the final rating was made by consensus with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials are provided, authors of the studies were contacted in order to obtain further information. Non-concurrence in quality assessment was reported.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-06-15 10:55:41 +0100" MODIFIED_BY="[Empty name]">
<P>1. Binary data<BR/>For binary outcomes we calculated a standard estimation of the fixed-effects risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). For statistically significant results we calculated the number needed to treat to provide benefit / to induce harm statistic (NNTB/H) and its 95% confidence interval (CI) using Visual Rx (http://www.nntonline.net/) taking account of the event rate in the control group.</P>
<P>2. Continuous data<BR/>For continuous outcomes we estimated a fixed-effect mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, where scales were of such similarity to allow presuming there was a small difference in measurement, we calculated it and, whenever possible, we transformed the effect back to the units of one or more of the specific instruments.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-05-11 14:27:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This can cause type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering is not accounted for in primary studies, we presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering had been incorporated into the analysis of primary studies, we present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC) [Design effect = 1 + (m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>2. Cross-over trials<BR/>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we will only use data of the first phase of cross-over studies.</P>
<P>3. Studies with multiple treatment groups<BR/>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, these data were not reproduced.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-05-12 16:21:23 +0100" MODIFIED_BY="[Empty name]">
<P>1. Overall loss of credibility<BR/>At some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2007" TYPE="REFERENCE">Xia 2007</LINK>). For any particular outcome should more than 50% of data be unaccounted for, we did not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias.</P>
<P>2. Binary<BR/>In the case where attrition for a binary outcome is between 0 and 50% and where these data were not clearly described, data were presented on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those lost to follow up were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death. A sensitivity analysis was undertaken testing how prone the primary outcomes were to change when 'completed' data only were compared to the intention-to-treat analysis using the above assumption.</P>
<P>3. Continuous<BR/>3.1 Attrition<BR/>In the case where attrition for a continuous outcome is between 0 and 50% and completer-only data were reported, we have reproduced these.</P>
<P>3.2 Standard deviations<BR/>Where there are missing measures of variance for continuous data but an exact standard error and confidence interval are available for group means, either &#8216;p&#8217; value or 't' value are available for differences in mean, we will calculate standard deviation value according to methods described in Section 7.7.3 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). If standard deviations were not reported and could not be calculated from available data, we asked authors to supply the data. </P>
<P>3.3 Last observation carried forward<BR/>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results. Therefore, where LOCF data has been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-05-11 20:37:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clinical heterogeneity<BR/>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying situations or people which we had not predicted would arise. Should such situations or participant groups have arisen they were fully discussed.</P>
<P>2. Methodological heterogeneity<BR/>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. Should such methodological outliers have arisen they were fully discussed.</P>
<P>3. Statistical<BR/>3.1 Visual inspection<BR/>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
<P>3.2 Employing the I<SUP>2</SUP>statistic<BR/>Heterogeneity between studies was investigated by considering the I<SUP>2</SUP> method alongside the Chi<SUP>2</SUP> 'p' value. The I<SUP>2</SUP> provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2</SUP> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. 'p' value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>).</P>
<P>I<SUP>2</SUP> estimate greater than or equal to 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic, was interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 - <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and reasons for heterogeneity were explored. If the inconsistency was high and the clear reasons were found, data were presented separately.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-03-03 08:23:43 +0000" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were ten or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-06-03 17:22:34 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible we employed a fixed-effect model for analyses. We understand that there is no closed argument for preference for use of fixed or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us, however, random-effects does put added weight onto the smaller of the studies - those trials that are most vulnerable to bias. It is for this reason we use the assumption-free fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-01-13 07:18:44 +0000" MODIFIED_BY="[Empty name]">
<P>1. Subgroup analyses<BR/>We anticipated no sub-group analyses.</P>
<P>2. Investigation of heterogeneity<BR/>2.1 Unanticipated heterogeneity<BR/>Should unanticipated clinical or methodological heterogeneity be obvious we will simply state hypotheses regarding these for future reviews or versions of this review. We do not anticipate undertaking analyses relating to these.</P>
<P>2.2 Anticipated heterogeneity<BR/>We did not anticipate any heterogeneity.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-05-11 14:39:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Implication of randomisation<BR/>We aimed to include trials in a sensitivity analysis if they are described in some way as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then all data were employed from these studies.</P>
<P>2. Assumptions for lost binary data<BR/>Where assumptions had to be made regarding people lost to follow up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>) we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discuss them but continued to employ our assumption.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-06-15 11:09:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-06-03 17:20:27 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-05-10 16:18:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. Original search - 2001<BR/>The previous version of this review (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>) undertook an extensive search covering several electronic databases listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>2. Updated search - 2009<BR/>The October 2009 update search of the Cochrane Schizophrenia Group's Register of Trials yielded an additional 104 references (from 69 studies). Initial screening reduced this figure to 15 references. After the initial evaluation, 13 trials were selected for further inspection and full texts of articles were ordered.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-05-11 21:09:52 +0100" MODIFIED_BY="[Empty name]">
<P>For detailed description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>The previous review, <LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>, included five trials (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>, <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>, <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>, <LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>). In addition to these, we added four studies from the new list of references (<LINK REF="STD-Wells-1991" TYPE="STUDY">Wells 1991</LINK>, <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>, <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>, <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>). Thus the present review includes nine studies.</P>
<P>1. Length of the trials<BR/>The duration of included trials varies from seven days (<LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>) to four months (<LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>).<BR/>Except for the latter which is a medium term study; the remainder all fall into the short-term category with a maximum duration of 12 weeks.</P>
<P>2. Setting<BR/>All trials are in-hospital studies with two (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK> and <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>) being conducted in the Psychiatric Intensive Care Unit. Seven trials were conducted in higher income countries such as the USA and UK, but two were undertaken in Brazil (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>) and Israel (<LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>).</P>
<P>3. Participants<BR/>In five trials all participants were adults with schizophrenia, although the diagnostic criteria used in the studies vary to a considerable extent (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>, <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>, <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>, <LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>). The core symptoms of schizophrenia, however, are fairly recognisable, which increases confidence that these studies are dealing with a broadly similar group of participants. The four trials reported the &#8220;majority&#8221; of participants as &#8220;adults with schizophrenia&#8221; (23 out of 32 <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>, 52/60 <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>, 29/39 <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>, 14/25 <LINK REF="STD-Wells-1991" TYPE="STUDY">Wells 1991</LINK>). These trials are included in the review. All participants were aged between 18 and 65 years old, with most being over 25 and under 55.</P>
<P>4. Study size<BR/>All studies were small. Numbers of participants in trials included ranged from eight (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>) to 60 (<LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>).</P>
<P>5. Intervention<BR/>A number of beta-blocking agents were used. Four trials used nadolol (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>; <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>; <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>; <LINK REF="STD-Wells-1991" TYPE="STUDY">Wells 1991</LINK>), the other four used propranolol (<LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>; <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>; <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>; <LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) and one trial used oxprenolol (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>) as the beta-blocking medication. <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK> was conducted as a three arm study where propranolol and placebo groups both were controls for a group allocated mirtazapine.</P>
<P>6. Outcomes<BR/>6.1 Mental state<BR/>6.1.1 Scale data<BR/>The studies used many different symptom rating scales for assessing treatment effects, however we were unable to use this scale data in the analysis. Some trialists (<LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) used standardised symptom scales but these scales were modified. In <LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK> and <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK> continuous outcome data on mental state were reported without variance. Specific reasons for excluding data from scales are given in the outcomes of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>6.2 Global state<BR/>The outcomes of global state had been pre-stipulated as the primary outcomes for this review. Data were available for leaving study early and relapse.</P>
<P>6.3 Adverse effects<BR/>We were able to extract the data for adverse effects: death, general problems and specific problems from every trial.</P>
<P>6.4 Missing outcomes<BR/>No usable data were available for quality of life, mental state, service use, burden on relatives, mean monthly cost of all care and satisfaction with care. </P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-06-03 17:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>For detailed description of studies please see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>1. Excluded studies<BR/>In the previous review 101 studies were excluded, most commonly because they used uncontrolled study designs. In the present review a further nine studies were excluded. Two were not randomised (<LINK REF="STD-Degwitz-1971" TYPE="STUDY">Degwitz 1971</LINK>, <LINK REF="STD-Kugler-1982" TYPE="STUDY">Kugler 1982</LINK>), three described participants as people with &#8220;chronic mental illness&#8221;, not schizophrenia (<LINK REF="STD-Hebenstreit-1986" TYPE="STUDY">Hebenstreit 1986</LINK>, <LINK REF="STD-Ratey-1990" TYPE="STUDY">Ratey 1990</LINK>, <LINK REF="STD-Sorgi-1992" TYPE="STUDY">Sorgi 1992</LINK>). One trial did not have a placebo as a comparator (<LINK REF="STD-Reiter-1987" TYPE="STUDY">Reiter 1987</LINK>), one did not have data at crossover point (<LINK REF="STD-Caspi-2001" TYPE="STUDY">Caspi 2001</LINK>) and two trials only reported on those who completed the study and it is unclear how many started the trial (<LINK REF="STD-Aoba-1996" TYPE="STUDY">Aoba 1996</LINK>, <LINK REF="STD-Maoz-2000" TYPE="STUDY">Maoz 2000</LINK>).</P>
<P>2. Awaiting assessment<BR/>There are no studies awaiting assessment.</P>
<P>3. Ongoing studies<BR/>We know of no ongoing studies.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-11 14:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>Summary of risk of bias across all included studies can be seen in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2010-05-11 14:49:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Adequate sequence generation<BR/>This aspect is poorly reported. Only <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK> gave the details on the randomised block design being used according to a table of random numbers. This trial was marked as "Yes" with the other eight trials marked as "Unclear" for the adequate sequence generation.</P>
<P>2. Allocation concealment<BR/>The authors of the original review stated that two trials were performed with adequate concealment of randomisation (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>, <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>) according to the information taken from personal communications. In all other trials the details of concealment of treatment allocation are not reported, and we do not have any further information on them. Therefore seven trials are judged as "Unclear" for allocation concealment, with two categorised as "Yes".</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-04-19 05:18:43 +0100" MODIFIED_BY="[Empty name]">
<P>Eight studies were reported as a double-blind trials, but there were no details on how it was done and whether or not blinding was successful. These studies were judged as "Yes" for blinding. In one trial (<LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) blindness was not stated but implied with no details given, so the judgement was "Unclear" for the blinding in this trial.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-05-11 14:51:13 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up rates at 12 weeks were as follows: <LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK> - 100%; <LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK> and <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK> - 94%; <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK> and <LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK> - 93%; <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK> and <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK> - 85%; <LINK REF="STD-Wells-1991" TYPE="STUDY">Wells 1991</LINK> - 80%; <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK> - 72%. We rated attrition bias for these included trials as low risk, as no systematic differences between the comparison groups (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) for loss of participants was found, and what is reported on attrition after allocation has not been consistently related to bias (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-05-11 14:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>We had no trial protocols. From the published papers it can be said that the methods described were consistent with outcomes reported. <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK> reported to a high standard and we rated it as "Yes" in the Risk of bias table with low risk of selective reporting. Eight other trials were rated as having a moderate risk of selective reporting and were marked as "Unclear" in the Risk of bias table. Three trials presented data in graphs which made it difficult to extract accurate data (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK> and <LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>). A number of trials (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>, <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>, <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>, <LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) did not report any measures of variance on continuous data, so some data on scales such as Brief Psychiatric Rating Scale could not be used for the purpose of this review. Only completer data were reported in a number of trials (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>, <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>, <LINK REF="STD-Wells-1991" TYPE="STUDY">Wells 1991</LINK>,<LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) but these studies did report the number of people starting the trial as well &#8211; unlike <LINK REF="STD-Aoba-1996" TYPE="STUDY">Aoba 1996</LINK> and <LINK REF="STD-Maoz-2000" TYPE="STUDY">Maoz 2000</LINK> which had to be excluded. One crossover trial (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>) did not report the data for phase one.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-05-11 14:53:25 +0100" MODIFIED_BY="[Empty name]">
<P>All trials were publicly funded and we found no obvious evidence of other bias occurring, we rated all trials, except for <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>, as of 'unclear' quality.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-06-15 11:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison 1. BETA-BLOCKERS versus PLACEBO</P>
<P>1. Global state<BR/>1.1 Leaving the study early - short term<BR/>Eight studies provided data on this outcome. Although, there was an indication that beta-blocker may be less acceptable as adjunct treatment for people with schizophrenia, the data are not statistically significant (n=274, 8 RCTs, RR at 12 weeks 1.62 CI 0.92 to 2.83, 'low' quality, (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>1.2 Relapse - as defined by study - short term<BR/>Data on relapse were difficult to extract as no author clearly defined the relapse. <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK> and <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK> reported one event each. In both cases the event took place in the beta-blocker group. No unspecified attrition or deterioration in mental state were reported in the other studies. Thus no significant difference was found between the groups in relapse rate, but the confidence interval is wide (n=68, 2 RCTs, RR at 12 weeks 3.12 CI 0.34 to 28.36, 'low' quality, <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>2. Adverse effects<BR/>2.1 Death<BR/>Data on mortality were possible to extract from all nine trials. There were no deaths reported and as such no differences between groups (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>2.2 General problems - short term<BR/>One trial reported two events, one of bronchoconstriction and one of bronchitis - both in the beta-blocker group (<LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>). Although data are in favour of placebo the difference is not statistically significant and the CI is very wide (n=48, 1RCTs, RR at 12 weeks 5.42 CI 0.27 to 107.20, 'low' quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>2.3 Specific problems cardiovascular - short term<BR/>Eight studies contributed data on this outcome and reported various outcomes many of which alluded to lowering of blood pressure. However, even when summated there was no indication that the addition of beta-blockers caused substantive problems (n=274, 8 RCTs, RR at 12 weeks 1.33 CI 0.47 to 3.74, 'low' quality (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Other typical adverse effects of beta-blockers such as acute heart failure, decrease of libido and impotence were not reported.<BR/>
</P>
<P>3. Outcomes with unusable data<BR/>3.1 Mental state<BR/>Average scores on the Brief Psychiatric Rating Scale (BPRS) tended to favour the nadolol group (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>, <LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) but, with no variance reported, we could not use the data for the purpose of this review. The other three trialists (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>, <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>, <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>) stated that some difference was detected in mental state between the groups which favoured the propranolol group. Although <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK> concluded in favour of beta-blockers, they did analyse only completer data (no ITT analysis). In <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>, the authors did not detect any difference in mental state between groups but, again without the mean and variance we could not include these data in our analysis. <LINK REF="STD-Wells-1991" TYPE="STUDY">Wells 1991</LINK> did not perform any rating for mental state.<BR/>
<BR/>3.2 Behaviour<BR/>
<LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK> reported completer data on clinical/behavioural improvement. They detected no clinically important improvement in either group. We were unable to use these data as no ITT (intention-to-treat) analysis could be performed. For the very same reason data from <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK> were not possible to include, although, they indicated a favourable outcome for those allocated nadolol. Behavioural change was rated on the Nurses' Observation Scale for In-patient Evaluation (NOSIE) scale in one trial (<LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>) and by nurses on a visual analogue scale in another trial (<LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>). These two trials reported a NOSIE rating difference in favour of propranolol, but again it was not possible to calculate a standardised mean due to missing data on variance.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-06-15 11:18:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-06-15 11:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Mental state<BR/>According to some trialists, beta-blockers have favourable effects on mental state of those with schizophrenia. Changes in mental state were measured using BPRS scale in five out of nine trials but they were poorly reported and in one case scale was modified by the author (<LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>) quite possibly threatening validity. A number of trials presented data only in graphs and failed to report variances (<LINK REF="STD-Allan-1996" TYPE="STUDY">Allan 1996</LINK>, <LINK REF="STD-Alpert-1990" TYPE="STUDY">Alpert 1990</LINK>, <LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>, <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>). This is a truely missed opportunity. It has wasted the time and effort of all those involved. If beta-blockers are effective these data do not prove it, and are testimony to how ill reporting can result in potentially effective treatments not being employed.</P>
<P>2. Global state<BR/>2.1 Leaving the study early - short term<BR/>Overall, few people left these short studies before completion (14%) and there were no clear differences between groups. Beta-blockers do not clearly increase intolerance of antipsychotic medications.</P>
<P>2.2 Relapse -as defined by study - short term<BR/>Only two relapses were reported, both in people taking beta-blockers <LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>, <LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>. The description of relapse varied widely from "deteriorating mental state with psychotic refusal to take pills" (<LINK REF="STD-Myers-1981" TYPE="STUDY">Myers 1981</LINK>), to "behavioural deterioration" (<LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>). It is possible that the relapses were caused by beta-blockers, but much larger studies are needed in order to clarify whether this is a consistent finding or just a random effect.</P>
<P>3. Adverse effects<BR/>3.1 Death<BR/>Deaths related to the use of beta-blockers are not common in people with no predisposing risk factors and some trialists excluded people with contra-indications for beta-blocker treatment. Due to the small numbers of trial participants and short duration of trials, rare adverse events such as death are not likely to have been detected. Although high doses of beta-blockers were used in some studies, the amount of medication was increased gradually, by small increments, and the physical status of participants closely monitored within hospital settings. If any adverse effects were observed the dose was reduced so the risk of adverse effects was probably lower than would be seen in routine clinical use.</P>
<P>3.2 General problems<BR/>Surprisingly there were a very small number of general adverse events reported. Only one case of bronchoconstriction and one of bronchitis were reported by one of the nine studies (<LINK REF="STD-Ratey-1992" TYPE="STUDY">Ratey 1992</LINK>). Both events were in beta-blocker group. Again there may be less occurrence of these effects as the use of the drugs was more regulated than would be usual in everyday care.</P>
<P>3.3 Specific problems<BR/>The most frequent adverse effect reported was related to hypotension. Beta-blockers typically lower blood pressure and because doses in these trials were high (up to 1920mg/day propranolol) compared with conventional use (320mg/day propranolol), even hypotensive collapse could be expected. The trialists did not report<I> </I>reasons for collapses, so a different aetiology, such as cardiac arrhythmia, is also possible. One of the three collapses reported in this review occurred in a participant on placebo. Again, if more studies were to be undertaken, we hope that adverse effects are recorded more thoroughly.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-06-15 11:16:39 +0100" MODIFIED_BY="[Empty name]">
<P>Authors of trials did try and measure mental state, global state, adverse effects and leaving early. Poor reporting means we have no data on mental state and few on all other outcomes. There are no data on quality of life, or costs. There are also no direct data on satisfaction and service use. Data that is available could well be applicable in everyday practice, they are just too few and too limited.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-06-15 11:18:26 +0100" MODIFIED_BY="[Empty name]">
<P>Many trials were excluded from this review due to poor study design. Only nine studies with a total of 282 participants met the inclusion criteria. All trials were small. Such studies were always unlikely to be powerful enough to show any difference between experimental and control groups, and even the compiled data of the 282 participants may not have been powerful enough to highlight meaningful differences. Some of the trials stated beta-blockers to be more effective for schizophrenia than placebo, but results of these studies were inadequately reported. In many cases data were not possible to extract for objective assessment.</P>
<P>Overall quality of trials in this review is presented in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. It was poor. Sequence generation was only clearly described in <LINK REF="STD-Poyurovsky-2006" TYPE="STUDY">Poyurovsky 2006</LINK>. Allocation concealment was explicit in two studies (<LINK REF="STD-Karniol-1982" TYPE="STUDY">Karniol 1982</LINK>, <LINK REF="STD-Pugh-1983" TYPE="STUDY">Pugh 1983</LINK>). Although blindness was stated to have been undertaken in all studies, it was neither described nor tested. Most trialists, however, attempted to give the reasons for leaving study early. Selective reporting was difficult to evaluate as no protocols were available.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-05-11 15:14:03 +0100" MODIFIED_BY="[Empty name]">
<P>We tried to be as objective as possible in extracting, summarising and synthesising the data. We are unaware of any prior beliefs that might had an impact on the outcome of this review. Electronic searches conducted for this review identified predominantly trials from high income countries. It is feasible that there are less accessible studies from elsewhere that we have missed. All included studies were small. Again, other small trials could have been hidden from our searches. However, we do not feel it likely that we have failed to identify studies that were large. Even if these had not originated from a less accessible literature, large studies probably would have come to light. Reporting bias were not possible to assess as we had no access to the protocols of the included studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-05-10 21:15:17 +0100" MODIFIED_BY="[Empty name]">
<P>This review substantially updates and largely concurs with findings from previous review (<LINK REF="REF-Cheine-2001" TYPE="REFERENCE">Cheine 2001</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-06-15 11:20:03 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-06-15 11:20:03 +0100" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>Currently data do not support any clear anti-psychotic effect of beta-blockers as an adjunct therapy to antipsychotic medication. We have no data on mental state, service use, satisfaction with treatment, quality of life. The limited data available on global state and adverse events that show beta-blockers have a beneficial effect similar to that of placebo.</P>
<P>2. For clinicians<BR/>Beta-blockers may help people in ways that have not been adequately measured in these studies. There is a possibility that through an improvement in motor symptoms, compliance will improve (<LINK REF="STD-Yorkston-1977" TYPE="STUDY">Yorkston 1977</LINK>). Data in relevant studies are too limited to help support a blanket policy, although there is a weak suggestion from some trials that there may be some benefits.</P>
<P>3. For policy makers<BR/>Policy makers need to consider how far the cost of providing beta-blocker adjunct treatment can be justified. It is possible that any effect would be subtle and that risks outweigh the benefits. Clinicians and policy makers should consider whether resources would be better deployed offering a treatment of more proven efficacy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-05-10 16:46:15 +0100" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>This review highlighted the need for the improvement of quality of reporting research findings. Adherence to the CONSORT checklist would encourage clarity, transparency and completeness in the reporting (<LINK REF="REF-Schulz-2010" TYPE="REFERENCE">Schulz 2010</LINK>).</P>
<P>2. Specific<BR/>We think that this review has demonstrated that there has not been enough basic research studying effects of beta-blocker in people with schizophrenia and that more trials could be justified and we suggest a design (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Future research in this area needs to consider an important outcomes on quality of life, satisfaction, healthy days, and cost effectiveness. 'Relapse' will need to be clearly defined in future studies.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-04-20 04:08:30 +0100" MODIFIED_BY="[Empty name]">
<P>Trial search coordinator Samantha Roberts is gratefully acknowledged for her efforts to retrieve the articles needed. The authors are indebted for all help and support provided by the staff at Cochrane Schizophrenia Group, Nottingham, UK. The protocol part of this review was updated using the template provided by the Cochrane Schizophrenia Group.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-04-20 04:06:41 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-30 17:46:50 +0100" MODIFIED_BY="[Empty name]">
<P>Elena Shek - wrote the protocol, instructed and trained co-reviewer, performed trial selection, data extraction and wrote the final report.</P>
<P>Sabyasachi Bhardan - helped to write the protocol, performed trial selection, data extraction and helped to write the final report.</P>
<P>Maxim Cheine - in original version of review helped write protocol, performed trial selection, data extraction and helped to write the final report.</P>
<P>Juha Ahonen - in original version of review helped write protocol, performed trial selection, data extraction and helped to write the final report.</P>
<P>Kristian Wahlbeck - in original version of review helped write protocol, performed trial selection, data extraction and helped to write the final report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-05-11 15:19:36 +0100" MODIFIED_BY="[Empty name]">
<P>This review is an update of an old review and incorporates largely revised methods, different from the original version (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We extended inclusion criteria which allowed four additional trials with a majority of participants with schizophrenia to be a part of this review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2010-04-20 04:06:12 +0100" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-05-11 20:35:50 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-05-11 09:44:52 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-05-10 21:47:56 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allan-1996" MODIFIED="2010-05-10 21:42:50 +0100" MODIFIED_BY="[Empty name]" NAME="Allan 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-10 21:42:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I</AU>
<TI>Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<PG>455-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:42:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpert-1990" MODIFIED="2010-05-10 21:43:15 +0100" MODIFIED_BY="[Empty name]" NAME="Alpert 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-10 21:43:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpert M, Allan ER, Citrome L, Laury G, Sison C, Sudilovsky A</AU>
<TI>A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1990</YR>
<VL>26</VL>
<PG>367-71</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:43:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karniol-1982" MODIFIED="2010-05-10 21:43:27 +0100" MODIFIED_BY="[Empty name]" NAME="Karniol 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-10 21:43:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karniol IG, Portela W</AU>
<TI>Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind, placebo-controlled, crossover study</TI>
<SO>Brazilian Journal of Medical Research</SO>
<YR>1982</YR>
<VL>15</VL>
<PG>389-94</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:43:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-1981" MODIFIED="2010-05-10 21:43:43 +0100" MODIFIED_BY="[Empty name]" NAME="Myers 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 21:43:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Myers DH, Campbell PL, Cocks NM, Flowerdew JA, Muir A</AU>
<TI>A trial of propranolol in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>139</VL>
<PG>118-21</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:43:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-2006" MODIFIED="2010-05-10 21:43:53 +0100" MODIFIED_BY="[Empty name]" NAME="Poyurovsky 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-10 21:43:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A</AU>
<TI>Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial</TI>
<SO>Biological Psychiatry</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>11</NO>
<PG>1071-7</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2010-05-10 21:43:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pugh-1983" MODIFIED="2010-05-10 21:44:03 +0100" MODIFIED_BY="[Empty name]" NAME="Pugh 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-05-10 21:44:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pugh CR, Steinert J, Priest RG</AU>
<TI>Propranolol in schizophrenia: a double-blind, placebo-controlled trial of propranolol as an adjunct to neuroleptic medication</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>143</VL>
<PG>151-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:44:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratey-1992" MODIFIED="2010-05-10 21:46:00 +0100" MODIFIED_BY="[Empty name]" NAME="Ratey 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-10 21:46:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratey JJ, Sorgi P, O´Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ, et al</AU>
<TI>Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1992</YR>
<VL>53</VL>
<PG>41-6</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:46:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-10 21:46:00 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1347291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-03 10:45:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong MK, Lee S</AU>
<TI>Nadolol in the treatment of aggression in chronic psychiatric inpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>6</NO>
<PG>235</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wells-1991" MODIFIED="2010-05-10 21:47:20 +0100" MODIFIED_BY="[Empty name]" NAME="Wells 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-10 21:47:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wells BG, Cold JA, Marken PA, Brown CS, Chu CC, Johnson RP, Nasdahl CS, Ayubi MA, Knott DH, Arheart KL</AU>
<TI>A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1991</YR>
<VL>52</VL>
<PG>255-60</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:47:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-10 21:47:20 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1676029 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yorkston-1977" MODIFIED="2010-05-10 21:47:56 +0100" MODIFIED_BY="[Empty name]" NAME="Yorkston 1977" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tyrer PJ</AU>
<TI>Propranolol in schizophrenia</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>761</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 21:47:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yorkston NJ, Gruzelier JH, Zaki SA, Hollander D, Pitcher DR, Sergeant HG</AU>
<TI>Propranolol as an adjunct to the treatment of schizophrenia</TI>
<SO>Propranolol and schizophrenia</SO>
<YR>1978</YR>
<PG>69-82</PG>
<ED>Roberts E, Amacher P</ED>
<PB>Liss</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2010-05-10 21:47:35 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 21:47:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston NJ, Gruzelier JH, Zaki SA, Hollander D, Pitcher DR, Sergeant HG</AU>
<TI>Propranolol as an adjunct to the treatment of schizophrenia</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>ii</VL>
<PG>575-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:47:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 21:47:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston NJ, Gruzelier JH, Zaki SA, Hollander D, Pitcher DR, Sergeant HG</AU>
<TI>Propranolol in chronic schizophrenia [letter]</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>1082-3</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:47:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-05-11 09:44:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1985" NAME="Adler 1985" YEAR="1985">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J</AU>
<TI>Efficacy of propranolol in neuroleptic-induced akathesia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>3</NO>
<PG>164-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1986" MODIFIED="2010-05-10 21:48:53 +0100" MODIFIED_BY="[Empty name]" NAME="Adler 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-10 21:48:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J</AU>
<TI>A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>149</VL>
<PG>42-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:48:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1989" MODIFIED="2010-05-10 21:49:05 +0100" MODIFIED_BY="[Empty name]" NAME="Adler 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-10 21:49:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler L, Duncan E, Angrist B, Hemdal P, Rotrosen J, Slotnick V</AU>
<TI>Effects of a specific beta 2-receptor blocker in neuroleptic-induced akathisia</TI>
<SO>Psychiatry Research</SO>
<YR>1989</YR>
<VL>27</VL>
<PG>1-4</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:49:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1990" MODIFIED="2010-05-10 21:49:27 +0100" MODIFIED_BY="[Empty name]" NAME="Adler 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-10 21:49:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler LA, Angrist B, Rotrosen J</AU>
<TI>Metoprolol versus propranolol</TI>
<SO>Biological Psychiatry</SO>
<YR>1990</YR>
<VL>27</VL>
<PG>673-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:49:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1991" NAME="Adler 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler LA, Angrist B, Fritz P, Rotrosen J, Mallya G, Lipinski JF Jr</AU>
<TI>Lack of efficacy of d-propranolol in neuroleptic-induced akathisia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1991</YR>
<VL>4</VL>
<NO>2</NO>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adler-1993" MODIFIED="2010-05-10 21:49:43 +0100" MODIFIED_BY="[Empty name]" NAME="Adler 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-10 21:49:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Adler LA, Peselow E, Rosenthal M, Angrist B</AU>
<TI>A controlled comparison of the effects of propranolol, benzropine, and placebo on akathisia: an interim analysis</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<PG>283-6</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:49:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ananth-1986" MODIFIED="2010-05-10 21:49:53 +0100" MODIFIED_BY="[Empty name]" NAME="Ananth 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-10 21:49:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ananth J, Lin KM</AU>
<TI>Propranolol in psychiatry. Therapeutic uses and side effects</TI>
<SO>Neuropsychobiology</SO>
<YR>1986</YR>
<VL>15</VL>
<PG>20-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:49:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aoba-1996" MODIFIED="2010-05-10 21:52:04 +0100" MODIFIED_BY="[Empty name]" NAME="Aoba 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-05-10 21:51:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aoba A, Murasaki M, Kamijima K, Yagi G, Komemushi S, Miura S</AU>
<TI>A beta-adrenoceptor antagonist, carteolol, in the treatment of neuroleptic-induced akathisia</TI>
<SO>Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30 - Oct 4; Venice, Italy</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 21:52:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aoba AM, Murasaki K, Kamijima G, Yagi S, Komemushi S, Miura S</AU>
<TI>A double-blind assessment of carteolol in the treatment of neuroleptic-induced akathisia</TI>
<SO>Proceedings of the XXth Collegium Internationale Neuro-psychopharmacologicum ;1996 Jun 23-25; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1970" MODIFIED="2010-05-10 21:52:13 +0100" MODIFIED_BY="[Empty name]" NAME="Atsmon 1970" YEAR="1970">
<REFERENCE MODIFIED="2010-05-10 21:52:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atsmon A, Blum I, Maoz B, Steiner M, Wysenbeek H</AU>
<TI>The effects of adrenergic blocking agents on psychotic patients</TI>
<SO>Harefuah</SO>
<YR>1970</YR>
<VL>79</VL>
<PG>20-1</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:52:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1971a" MODIFIED="2010-05-10 21:53:10 +0100" MODIFIED_BY="[Empty name]" NAME="Atsmon 1971a" YEAR="1971">
<REFERENCE MODIFIED="2010-05-10 21:53:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atsmon A</AU>
<TI>Propranolol in high doses in psychiatry</TI>
<TO>Le propranolol à hautes doses en psychiatrie</TO>
<SO>Presse Medicale</SO>
<YR>1971</YR>
<VL>79</VL>
<PG>740</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1971b" MODIFIED="2010-05-10 21:53:23 +0100" MODIFIED_BY="[Empty name]" NAME="Atsmon 1971b" YEAR="1971">
<REFERENCE MODIFIED="2010-05-10 21:53:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atsmon A, Blum I, Wijsenbeek H, Maoz B, Steiner M, Ziegelman G</AU>
<TI>The short-term effects of adrenergic-blocking agents in a small group of psychotic patients. Preliminary clinical observations</TI>
<SO>Psychiatria Neurologia Neurochirurgia</SO>
<YR>1971</YR>
<VL>74</VL>
<PG>251-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:53:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1972" MODIFIED="2010-05-10 21:53:31 +0100" MODIFIED_BY="[Empty name]" NAME="Atsmon 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-05-10 21:53:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atsmon A, Blum I, Steiner M, Latz A, Wijsenbeek H</AU>
<TI>Further studies with propranolol in psychotic patients</TI>
<SO>Psychopharmacologia</SO>
<YR>1972</YR>
<VL>27</VL>
<PG>249-54</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:53:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1976" NAME="Atsmon 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atsmon A</AU>
<TI>Early observations of the effect of propranolol on psychotic patients</TI>
<SO>Advanced Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>12</VL>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1978a" MODIFIED="2010-05-10 21:53:48 +0100" MODIFIED_BY="[Empty name]" NAME="Atsmon 1978a" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 21:53:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Atsmon A, Blum I</AU>
<TI>Beta-adrenergic blocking drugs in psychiatry: present status, future approaches and research</TI>
<SO>Encephale</SO>
<YR>1978</YR>
<VL>4</VL>
<PG>173-86</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:53:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atsmon-1978b" MODIFIED="2010-05-10 21:53:59 +0100" MODIFIED_BY="[Empty name]" NAME="Atsmon 1978b" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 21:53:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Atsmon A, Blum I</AU>
<TI>Propranolol and schizophrenia: the discovery</TI>
<SO>Propranolol and schizophrenia</SO>
<YR>1978</YR>
<PG>5-38</PG>
<ED>Roberts E, Amacher P</ED>
<PB>Liss</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2010-05-10 21:53:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auriol-1972" MODIFIED="2010-05-11 09:21:25 +0100" MODIFIED_BY="[Empty name]" NAME="Auriol 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-05-11 09:21:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Auriol B, Palandjian N, Bord M, Vals A</AU>
<TI>Beta-blockers in psychiatry</TI>
<TO>Les béta-blocquants en psychiatrie</TO>
<SO>La Nouvelle Presse Médicale</SO>
<YR>1972</YR>
<VL>1</VL>
<PG>1439</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:54:46 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auriol-1973" MODIFIED="2010-05-10 21:55:57 +0100" MODIFIED_BY="[Empty name]" NAME="Auriol 1973" YEAR="1973">
<REFERENCE MODIFIED="2010-05-10 21:55:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Auriol B, Pinar N, Bord M</AU>
<TI>Pindolol: a new psychotropic</TI>
<TO>Le pindolol: un nouveau psychotrope</TO>
<SO>Encephale</SO>
<YR>1973</YR>
<VL>62</VL>
<PG>427-41</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:54:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bacher-1980" MODIFIED="2010-05-10 21:56:14 +0100" MODIFIED_BY="[Empty name]" NAME="Bacher 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-05-10 21:56:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bacher NM, Lewis HA</AU>
<TI>Low-dose propranolol in tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>495-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:56:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 21:56:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Risch SC, Cohen RM, Kalin NH</AU>
<TI>Propranolol, chlorpromazine, and tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>1125</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:56:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belmaker-1991" NAME="Belmaker 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Belmaker RH, Lerer B, Newman M, Fuchs I</AU>
<TI>Lack of effect of lithium, propranolol or haloperidol on basal plasma cyclic AMP levels</TI>
<SO>Lithium</SO>
<YR>1991</YR>
<VL>2</VL>
<PG>115-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bigelow-1978" NAME="Bigelow 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Bigelow LB, Zalcman S, Kleinman JE, Weinberger D, Luchins D, Tallman J, Karoum F, Wyatt RJ</AU>
<TI>Propranolol treatment of chronic schizophrenia: clinical response, catecholamine metabolism and lymphocyte B-reseptors</TI>
<SO>Catecholamines: basic and clinical frontiers</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>1851-53</PG>
<ED>Usdin E et al</ED>
<PB>Pergamon Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carlsson-1970" NAME="Carlsson 1970" YEAR="1970">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carlsson C, Johanson T</AU>
<TI>Effects of propranolol (Inderal) on psychiatric symptoms in chronic alcoholism</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>Suppl 217</VL>
<PG>S58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caspi-2001" MODIFIED="2010-05-10 21:58:38 +0100" MODIFIED_BY="[Empty name]" NAME="Caspi 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-10 21:58:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caspi N, Modai Ilan, Barak P, Waisbourd A, Zbarsky H, Hirschmann S, Ritsner M</AU>
<TI>Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>2</NO>
<PG>111-5</PG>
<PB>Lippincott Williams and Wilkins.</PB>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2010-05-10 21:57:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 21:58:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modai I, Caspi N, Barak P, Waisbourd A, Zbarsky E, Hirschmann S, Ritsner M</AU>
<TI>Pindolol augmentation in aggressive schizophrenic patients</TI>
<SO>Proceedings of the 11th Congress of the Association of European Psychiatrists; 2002 May 4-8; Stockholm, Sweden</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>182s</PG>
<ED>Lindefors N, Nyback H, Sedvall GC, Wiesel F-A</ED>
<IDENTIFIERS MODIFIED="2010-05-10 21:58:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christison-1991" MODIFIED="2010-05-10 21:58:47 +0100" MODIFIED_BY="[Empty name]" NAME="Christison 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-10 21:58:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Christison GW, Kirch DG, Wyatt RJ</AU>
<TI>When symptoms persist: choosing among alternative somatic treatments for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>217-45</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:58:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1989" MODIFIED="2010-05-10 21:58:59 +0100" MODIFIED_BY="[Empty name]" NAME="Cooper 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-10 21:58:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cooper SJ, Doherty MM, King DJ</AU>
<TI>Tardive dystonia. The benefits of time [see comments]</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>155</VL>
<PG>113-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:58:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daskalopoulos-1979" MODIFIED="2010-05-10 21:59:55 +0100" MODIFIED_BY="[Empty name]" NAME="Daskalopoulos 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 21:59:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-05-10 21:59:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daskalopoulos N</AU>
<TI>The psychotropic effects of a new beta-blocker, acebutolol, among psychotic</TI>
<TO>Les effets psychotropes d'un nouveau bêta-bloquant, l'acébutolol, chez les psychotiques</TO>
<SO>Annales Medico Psychologiquies Paris</SO>
<YR>1979</YR>
<VL>137</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2010-05-10 21:59:55 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Degwitz-1971" MODIFIED="2010-05-10 22:02:18 +0100" MODIFIED_BY="[Empty name]" NAME="Degwitz 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-05-10 22:02:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Degwitz R</AU>
<TI>Experience with high doses of a beta-receptor blocking agent (Trasicor) in cases of exited psychosis</TI>
<SO>Proceedings of the Vth World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Mexico City, Mexico</SO>
<YR>1971</YR>
<PB>La Prensa Medica Mexicana, S.A. Fournier</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dominguez-1984" MODIFIED="2010-05-10 22:02:28 +0100" MODIFIED_BY="[Empty name]" NAME="Dominguez 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-05-10 22:02:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dominguez RA, Goldstein BJ</AU>
<TI>Beta-blockers in psychiatry</TI>
<SO>Hospital &amp; Community Psychiatry</SO>
<YR>1984</YR>
<VL>35</VL>
<PG>565-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:02:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dupuis-1987" MODIFIED="2010-05-10 22:02:36 +0100" MODIFIED_BY="[Empty name]" NAME="Dupuis 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-10 22:02:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dupuis B, Catteau J, Dumon JP, Libert C, Petit H</AU>
<TI>Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<PG>802-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:02:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eccleston-1985" MODIFIED="2010-05-10 22:02:44 +0100" MODIFIED_BY="[Empty name]" NAME="Eccleston 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-05-10 22:02:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eccleston D, Fairbairn AF, Hassanyeh F, McClelland HA, Stephens DA</AU>
<TI>The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1985</YR>
<VL>147</VL>
<PG>623-30</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:02:44 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elizur-1978" NAME="Elizur 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Elizur A, Segal Z, Yeret A, Davidson S, Ben-David M</AU>
<TI>Antipsychotic activity and mode of action of propranolol versus neuroleptic drugs</TI>
<SO>Israel Journal of Medical Science</SO>
<YR>1978</YR>
<VL>14</VL>
<PG>493-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elizur-1979a" MODIFIED="2010-05-10 22:03:00 +0100" MODIFIED_BY="[Empty name]" NAME="Elizur 1979a" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:03:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Elizur A, Segal Z, Yeret A, Davidson S, Atsmon A</AU>
<TI>Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen</TI>
<SO>Psychopharmacology Berlin</SO>
<YR>1979</YR>
<VL>60</VL>
<PG>189-94</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:03:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elizur-1979b" MODIFIED="2010-05-10 22:03:09 +0100" MODIFIED_BY="[Empty name]" NAME="Elizur 1979b" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:03:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Elizur A, Segal S, Yeret A, Ben-David M</AU>
<TI>Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients</TI>
<SO>Israel Annals of Psychiatry and Related Disciplines</SO>
<YR>1979</YR>
<VL>17</VL>
<PG>318-27</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:03:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-1997" MODIFIED="2010-05-10 22:03:17 +0100" MODIFIED_BY="[Empty name]" NAME="Fava 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-05-10 22:03:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fava M</AU>
<TI>Psychopharmacologic treatment of pathologic aggression</TI>
<SO>Psychiatric Clinics of North America</SO>
<YR>1997</YR>
<VL>20</VL>
<PG>427-51</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:03:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Floru-1974" MODIFIED="2010-05-10 22:03:26 +0100" MODIFIED_BY="[Empty name]" NAME="Floru 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-05-10 22:03:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Floru L, Tegeler J</AU>
<TI>Therapeutic significance of the beta-receptor blockade in lithium-induced tremor. Therapeutic trials with pindolol and practolol</TI>
<SO>Medizinische Welt</SO>
<YR>1974</YR>
<VL>25</VL>
<PG>450</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:03:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Floru-1979" MODIFIED="2010-05-10 22:03:34 +0100" MODIFIED_BY="[Empty name]" NAME="Floru 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:03:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Floru L, Brosteanu ER, Lehmann E, Schottenfeld Y</AU>
<TI>Treatment of neuroleptic-induced tremor with the beta-blocker bupranolol</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1979</YR>
<VL>29</VL>
<PG>142-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:03:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardos-1973a" MODIFIED="2010-05-10 22:03:43 +0100" MODIFIED_BY="[Empty name]" NAME="Gardos 1973a" YEAR="1973">
<REFERENCE MODIFIED="2010-05-10 22:03:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gardos G, Cole JO, Volicer L, Orzack MH, Oliff AC</AU>
<TI>A dose-response study of propranolol in chronic schizophrenics</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1973</YR>
<VL>15</VL>
<PG>314-23</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:03:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardos-1973b" NAME="Gardos 1973b" YEAR="1973">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gardos G, Cole JO, Orzack MH, Volicer L</AU>
<TI>Propranolol in treatment-resistant schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1973</YR>
<VL>9</VL>
<PG>43-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gershon-1979" MODIFIED="2010-05-10 22:04:00 +0100" MODIFIED_BY="[Empty name]" NAME="Gershon 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:04:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gershon ES, Goldstein RE, Moss AJ, Van-Kammen DP</AU>
<TI>Psychosis with ordinary doses of propranolol</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1979</YR>
<VL>90</VL>
<PG>938-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:04:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilligan-1972" MODIFIED="2010-05-10 22:04:13 +0100" MODIFIED_BY="[Empty name]" NAME="Gilligan 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-05-10 22:04:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gilligan BS, Veale JL, Wodak J</AU>
<TI>Propranolol in the treatment of tremor</TI>
<SO>Medical Journal of Australia</SO>
<YR>1972</YR>
<VL>1</VL>
<PG>320-2</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:04:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greendyke-1988" MODIFIED="2010-05-10 22:04:20 +0100" MODIFIED_BY="[Empty name]" NAME="Greendyke 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-10 22:04:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Greendyke RM, Webster J, Kim J, Kim H</AU>
<TI>Lack of efficacy of pindolol in tardive dyskinesia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1988</YR>
<VL>145</VL>
<PG>1318-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:04:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruzelier--1978" MODIFIED="2010-05-10 22:05:09 +0100" MODIFIED_BY="[Empty name]" NAME="Gruzelier  1978" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 22:05:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Gruzelier JH, Yorkston NJ</AU>
<TI>Propranolol and schizophrenia: objective evidence of efficacy</TI>
<SO>The Biological Bases of Schizophrenia</SO>
<YR>1978</YR>
<PG>127-46</PG>
<ED>Hemming W, Hemmings G</ED>
<PB>MTP Press</PB>
<CY>Lancaster</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruzelier-1979" MODIFIED="2010-05-10 22:05:15 +0100" MODIFIED_BY="[Empty name]" NAME="Gruzelier 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:05:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gruzelier JH, Hirsch SR, Weller M, Murphy C</AU>
<TI>Influence of D- or DL-propranolol and chlorpromazine on habituation of phasic electrodermal responses in schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1979</YR>
<VL>60</VL>
<PG>241-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:05:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruzelier-1980" MODIFIED="2010-05-10 22:05:21 +0100" MODIFIED_BY="[Empty name]" NAME="Gruzelier 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-05-10 22:05:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gruzelier J, Thornton S, Staniforth D, Zaki S, Yorkston N</AU>
<TI>Active and passive avoidance learning in controls and schizophrenic patients on racemic propranolol and neuroleptics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>131-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:05:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanssen-1978a" MODIFIED="2010-05-11 09:44:52 +0100" MODIFIED_BY="[Empty name]" NAME="Hanssen 1978a" YEAR="1978">
<REFERENCE MODIFIED="2010-05-11 09:44:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanssen T, Heyden T, Sundberg I, Alfredsson G, Nybäck H, Wetterberg L</AU>
<TI>Propranololbehandling in schizophrenia</TI>
<TO>Propranololbehandling vid schizofreni</TO>
<SO>Nordisk Psykiatrisk Tidsskrift</SO>
<YR>1978</YR>
<VL>32</VL>
<PG>393-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanssen-1978b" MODIFIED="2010-05-10 22:07:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hanssen 1978b" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 22:07:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanssen T, Heyden T, Sundberg I, Wetterberg L, Eneroth P</AU>
<TI>Decrease in serum-prolactin after propranolol in schizophrenia</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>1</VL>
<PG>101-2</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:07:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanssen-1980" MODIFIED="2010-05-10 22:07:09 +0100" MODIFIED_BY="[Empty name]" NAME="Hanssen 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-05-10 22:07:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hanssen T, Heyden T, Sundberg I, Alfredsson G, Nyback H, Wetterberg L</AU>
<TI>Propranolol in schizophrenia. Clinical, metabolic and pharmacological findings</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1980</YR>
<VL>37</VL>
<PG>685-90</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:07:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hayes-1983" MODIFIED="2010-05-10 22:07:16 +0100" MODIFIED_BY="[Empty name]" NAME="Hayes 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-05-10 22:07:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hayes PE, Schulz SC</AU>
<TI>The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia</TI>
<SO>Pharmacotherapy</SO>
<YR>1983</YR>
<VL>3</VL>
<PG>101-17</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:07:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hebenstreit-1986" MODIFIED="2010-05-10 22:07:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hebenstreit 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-10 22:07:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hebenstreit GF, Hoffmann H, Hoffmann W, Pittner H</AU>
<TI>Beta blockade with celiprolol in tardive dyskinesia patients treated with neuroleptics</TI>
<TO>Betablockade mit Celiprolol bei neuroleptikabehandelten patienten mit tardiver dyskinesie</TO>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1986</YR>
<VL>98</VL>
<PG>388-92</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:07:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinshelwood-1969" MODIFIED="2010-05-10 22:07:41 +0100" MODIFIED_BY="[Empty name]" NAME="Hinshelwood 1969" YEAR="1969">
<REFERENCE MODIFIED="2010-05-10 22:07:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hinshelwood RD</AU>
<TI>Hallucinations and propranolol</TI>
<SO>British Medical Journal</SO>
<YR>1969</YR>
<VL>2</VL>
<PG>445</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:07:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-1981" MODIFIED="2010-05-10 22:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Hirsch 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 22:07:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch SR, Manchanda R, Weller MPI</AU>
<TI>Dextro-propranolol in schizophrenia</TI>
<SO>Progress in Neuropsychopharmacology</SO>
<YR>1981</YR>
<VL>4</VL>
<PG>633-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:07:48 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irwin-1988" MODIFIED="2010-05-10 22:08:24 +0100" MODIFIED_BY="[Empty name]" NAME="Irwin 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-10 22:08:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Irwin M, Sullivan G, Van-Putten T</AU>
<TI>Propranolol as a primary treatment of neuroleptic-induced akathisia</TI>
<SO>Hillside Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>10</VL>
<PG>244-50</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:08:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jefferson-1974" MODIFIED="2010-05-10 22:08:30 +0100" MODIFIED_BY="[Empty name]" NAME="Jefferson 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-05-10 22:08:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jefferson JW</AU>
<TI>Beta-adrenergic receptor blocking drugs in psychiatry</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1974</YR>
<VL>31</VL>
<PG>681-91</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:08:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-1980" MODIFIED="2010-05-10 22:08:36 +0100" MODIFIED_BY="[Empty name]" NAME="King 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-05-10 22:08:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>King DJ, Turkson SN, Liddle J, Kinney CD</AU>
<TI>Some clinical and metabolical aspects of propranolol in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>458-68</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:08:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-1983" MODIFIED="2010-05-10 22:08:47 +0100" MODIFIED_BY="[Empty name]" NAME="King 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-05-10 22:08:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>King DJ, Cooper SJ, Liddle J</AU>
<TI>The effect of propranolol on CSF amine metabolites in psychiatric patients</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>15</VL>
<PG>331-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:08:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1988" MODIFIED="2010-05-10 22:08:56 +0100" MODIFIED_BY="[Empty name]" NAME="Kramer 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-10 22:08:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Gorkin RA, DiJohnson C, Sheves P</AU>
<TI>Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study</TI>
<SO>Biological Psychiatry</SO>
<YR>1988</YR>
<VL>24</VL>
<PG>823-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:08:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1989" MODIFIED="2010-05-10 22:09:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kramer 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-10 22:09:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Gorkin R, DiJohnson C</AU>
<TI>Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study</TI>
<SO>Hillside Journal of Clinical Psychiatry</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>107-19</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:09:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kugler-1982" MODIFIED="2010-05-10 22:09:22 +0100" MODIFIED_BY="[Empty name]" NAME="Kugler 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-10 22:09:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kugler BT, Caudrey DJ, Gruzelier JH</AU>
<TI>Bilateral auditory acuity of schizophrenic patients: effects of repeated testing, time of day and medication</TI>
<SO>Psychological Medicine</SO>
<YR>1982</YR>
<VL>12</VL>
<PG>775-81</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:09:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lader-1988" MODIFIED="2010-05-10 22:09:32 +0100" MODIFIED_BY="[Empty name]" NAME="Lader 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-10 22:09:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lader M</AU>
<TI>Beta-adrenoceptor antagonists in neuropsychiatry: an update</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<PG>213-23</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:09:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindstr_x00f6_m-1980" MODIFIED="2010-05-10 22:09:39 +0100" MODIFIED_BY="[Empty name]" NAME="Lindström 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-05-10 22:09:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindström LH, Persson E</AU>
<TI>Propranolol in schizophrenia: a controlled study in neuroleptic-treated patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>126-30</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:09:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipinski-1988" MODIFIED="2010-05-10 22:09:50 +0100" MODIFIED_BY="[Empty name]" NAME="Lipinski 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-05-10 22:09:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lipinski JF, Keck PE Jr, McElroy SL</AU>
<TI>Beta-adrenergic antagonists in psychosis: is improvement due to treatment of neuroleptic-induced akathisia?</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1988</YR>
<VL>8</VL>
<PG>409-16</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:09:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malas-1981" MODIFIED="2010-05-10 22:10:03 +0100" MODIFIED_BY="[Empty name]" NAME="Malas 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 22:10:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Malas KL, De Fraites EG, Van Kammen DP</AU>
<TI>Neuroendocrine effects of DL-propranolol</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>424</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:10:03 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manchanda-1986" MODIFIED="2010-05-10 22:10:17 +0100" MODIFIED_BY="[Empty name]" NAME="Manchanda 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-10 22:10:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Manchanda R, Hirsch SR</AU>
<TI>Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>148</VL>
<PG>701-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:10:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 22:10:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manchanda R</AU>
<TI>Dextro-propranolol and depressive symptoms in a schizophrenic population</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1987</YR>
<VL>11</VL>
<PG>625-32</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:10:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maoz-2000" MODIFIED="2010-05-10 22:14:18 +0100" MODIFIED_BY="[Empty name]" NAME="Maoz 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-05-10 22:14:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maoz G, Stein D, Meged S, Kurzman L, Levine J, Valevski A, Aviv A, Sirota P, Kraus R, Weizman A, Berger BD</AU>
<TI>The antiaggressive action of combined haloperidol-propranolol treatment in schizophrenia</TI>
<SO>European Psychologist</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>4</NO>
<PG>312-25</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:10:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marsden-1967" MODIFIED="2010-05-10 22:14:27 +0100" MODIFIED_BY="[Empty name]" NAME="Marsden 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-05-10 22:14:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Marsden CD, Foley TH, Owen DA, McAllister RG</AU>
<TI>Peripheral beta-adrenergic receptors concerned with tremor</TI>
<SO>Clinical Science</SO>
<YR>1967</YR>
<VL>33</VL>
<PG>53-65</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:14:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-May-1965" NAME="May 1965" YEAR="1965">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>May P, Tuma H</AU>
<TI>Treatment of schizophrenia. An experimental study of five treatment methods</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1965</YR>
<VL>111</VL>
<PG>503-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-May-1976" MODIFIED="2010-05-10 22:14:39 +0100" MODIFIED_BY="[Empty name]" NAME="May 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-05-10 22:14:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>May PRA, Tuma AH, Dixon WJ</AU>
<TI>Schizophrenia - a follow-up study of results of treatment</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>474-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:14:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metzer-1993" MODIFIED="2010-05-10 22:14:50 +0100" MODIFIED_BY="[Empty name]" NAME="Metzer 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-10 22:14:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Metzer WS, Paige SR, Newton JEO</AU>
<TI>Inefficacy of propranolol in attenuation of drug-induced parkinsonian tremor</TI>
<SO>Movement Disorders</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>43-6</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:14:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1982" MODIFIED="2010-05-10 22:14:57 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-10 22:14:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Miller FA, Rampling D</AU>
<TI>Adverse effects of combined propranolol and chlorpromazine therapy</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>1198-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:14:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-1979" MODIFIED="2010-05-10 22:15:19 +0100" MODIFIED_BY="[Empty name]" NAME="Möller 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:15:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Von Zerssen D, Emrich HM, Kissling W, Cording C, Schietsch HJ, Riedel E</AU>
<TI>Action of d-propranolol in manic psychoses</TI>
<SO>Archiv für Psychiatrie und Nervenkrankheiten</SO>
<YR>1979</YR>
<VL>227</VL>
<PG>301-17</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:15:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orzack-1973" MODIFIED="2010-05-10 22:15:27 +0100" MODIFIED_BY="[Empty name]" NAME="Orzack 1973" YEAR="1973">
<REFERENCE MODIFIED="2010-05-10 22:15:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Orzack M, Branconnier R, Gardos G</AU>
<TI>CNS effects of propranolol in man</TI>
<SO>Psychopharmacologia</SO>
<YR>1973</YR>
<VL>29</VL>
<PG>299-306</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:15:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peet-1981a" MODIFIED="2010-05-10 22:15:34 +0100" MODIFIED_BY="[Empty name]" NAME="Peet 1981a" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 22:15:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peet M</AU>
<TI>Is propranolol antischizophrenic?</TI>
<SO>Neuropharmacology</SO>
<YR>1981</YR>
<VL>20</VL>
<PG>1303-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:15:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peet-1981b" MODIFIED="2010-05-10 22:15:50 +0100" MODIFIED_BY="[Empty name]" NAME="Peet 1981b" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 22:15:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Middlemiss DN, Yates RA</AU>
<TI>Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients [letter]</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>2</VL>
<PG>978</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:15:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 22:15:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Middlemiss DN, Yates RA</AU>
<TI>Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>139</VL>
<PG>112-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:15:50 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peet-1981c" MODIFIED="2010-05-10 22:15:58 +0100" MODIFIED_BY="[Empty name]" NAME="Peet 1981c" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 22:15:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peet M, Bethell MS, Coates A, Khamnee AK, Hall P, Cooper SJ, King DJ, Yates RA</AU>
<TI>Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>139</VL>
<PG>105-11</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:15:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peters-1978" MODIFIED="2010-05-10 22:16:08 +0100" MODIFIED_BY="[Empty name]" NAME="Peters 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 22:16:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peters NL, Anderson KC, Reid PR, Taylor GJ</AU>
<TI>Acute mental status changes caused by propranolol</TI>
<SO>John Hopkins Medical Journal</SO>
<YR>1978</YR>
<VL>143</VL>
<PG>163-4</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:16:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poli-1984" MODIFIED="2010-05-11 09:04:54 +0100" MODIFIED_BY="[Empty name]" NAME="Poli 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-05-11 09:04:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Poli A, Palermo-Neto J</AU>
<TI>Effect of propranolol in the central nervous system: antischizophrenic action</TI>
<TO>Efeitos do propranolol no sistema nervoso central: acao antiesquizofrenica</TO>
<SO>Revista Paulista de Medicina</SO>
<YR>1984</YR>
<VL>102</VL>
<PG>215-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:16:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rackensperger-1974" MODIFIED="2010-05-10 22:19:11 +0100" MODIFIED_BY="[Empty name]" NAME="Rackensperger 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-05-10 22:19:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rackensperger W, Gaupp R, Mattke DJ, Schwarz D, Stutte KH</AU>
<TI>Treatment of acute schizophrenic psychoses with beta-blockers reseptoren</TI>
<TO>Behandlung von akuten schizophrenen psychosen mit beta-reseptoren-blockern</TO>
<SO>Archiv für Psychiatrie und Nervenkrankheiten</SO>
<YR>1974</YR>
<VL>219</VL>
<PG>29-36</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:19:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratey-1990" MODIFIED="2010-05-10 22:19:19 +0100" MODIFIED_BY="[Empty name]" NAME="Ratey 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-05-10 22:19:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ratey J, Sorgi P, Lindem K, ,</AU>
<TI>Nadolol treat aggression and psychiatric symptomatology in chronic psychiatric inpatients</TI>
<SO>Schizophrenia Research</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>1</NO>
<PG>49</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:19:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratey-1991" MODIFIED="2010-05-10 22:19:49 +0100" MODIFIED_BY="[Empty name]" NAME="Ratey 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-05-10 22:19:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ratey JJ, Gutheil CM</AU>
<TI>The measurement of aggressive behavior: reflections on the use of the overt aggression scale and the modified overt aggression Scale</TI>
<SO>Journal of Neuropsychiatry and Clinical Neuroscience</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>57-60</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:19:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reiter-1987" MODIFIED="2010-05-10 22:19:58 +0100" MODIFIED_BY="[Empty name]" NAME="Reiter 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-05-10 22:19:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reiter S, Adler L, Angrist B, Corwin J, Rotrosen J</AU>
<TI>Atenolol and propranolol in neuroleptic-induced akathisia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>4</NO>
<PG>279-80</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:19:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remington-1993" MODIFIED="2010-05-10 22:20:11 +0100" MODIFIED_BY="[Empty name]" NAME="Remington 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-05-10 22:20:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Remington G, Fornazzari L, Sethna R</AU>
<TI>Placebo response in refractory tardive akathisia</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>38</VL>
<PG>248-50</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:20:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ridges-1977" MODIFIED="2010-05-10 22:20:20 +0100" MODIFIED_BY="[Empty name]" NAME="Ridges 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-05-10 22:20:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ridges AP, Lawton K, Harper P, Ghosh C, Hindson N</AU>
<TI>Propranolol in schizophrenia</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>2</VL>
<PG>986</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:20:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritrovato-1989" MODIFIED="2010-05-10 22:20:28 +0100" MODIFIED_BY="[Empty name]" NAME="Ritrovato 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-05-10 22:20:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ritrovato CA, Weber SS, Dufresne RL</AU>
<TI>Nadolol in the treatment of aggressive behavior associated with schizophrenia</TI>
<SO>Clinical Pharmacy</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>132-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:20:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachdev-1993a" MODIFIED="2010-05-10 22:20:36 +0100" MODIFIED_BY="[Empty name]" NAME="Sachdev 1993a" YEAR="1993">
<REFERENCE MODIFIED="2010-05-10 22:20:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sashdev P, Loneragan C</AU>
<TI>Intravenous benztropine and propranolol challenges in acute neuroleptic-induced akathisia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>324-31</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:20:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sachdev-1993b" MODIFIED="2010-05-10 22:20:43 +0100" MODIFIED_BY="[Empty name]" NAME="Sachdev 1993b" YEAR="1993">
<REFERENCE MODIFIED="2010-05-10 22:20:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sachdev P, Loneragan C</AU>
<TI>Intravenous benztropine and propranolol challenges in tardive akathisia</TI>
<SO>Psychopharmacology</SO>
<YR>1993</YR>
<VL>113</VL>
<PG>119-22</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:20:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scharbach-1981" NAME="Scharbach 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scharbach H</AU>
<TI>A double blind trial: oxprenolol/diazepam</TI>
<SO>Encephale</SO>
<YR>1981</YR>
<VL>7</VL>
<NO>1</NO>
<PG>51-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scheinin-1984" MODIFIED="2010-05-10 22:21:04 +0100" MODIFIED_BY="[Empty name]" NAME="Scheinin 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-05-10 22:21:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Scheinin M, Van Kammen DP, Ninan PT, Linnoila M</AU>
<TI>Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1984</YR>
<VL>36</VL>
<PG>33-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:21:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoenen-1978" MODIFIED="2010-05-10 22:21:11 +0100" MODIFIED_BY="[Empty name]" NAME="Schoenen 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 22:21:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schoenen J, Delwaide PJ</AU>
<TI>Indications for beta-blockers in neurology</TI>
<SO>Acta Clinica Belgica</SO>
<YR>1978</YR>
<VL>33</VL>
<PG>130-40</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:21:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schrodt-1982" MODIFIED="2010-05-10 22:21:19 +0100" MODIFIED_BY="[Empty name]" NAME="Schrodt 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-10 22:21:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schrodt GR, Wright JH, Simpson R, Moore DP, Chase S</AU>
<TI>Treatment of tardive dyskinesia with propranolol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1982</YR>
<VL>43</VL>
<PG>328-31</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:21:19 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sethi-1983" NAME="Sethi 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sethi BB, Dube S</AU>
<TI>Propranolol in schizophrenia</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1983</YR>
<VL>7</VL>
<NO>1</NO>
<PG>89-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheppard-1979" MODIFIED="2010-05-10 22:21:34 +0100" MODIFIED_BY="[Empty name]" NAME="Sheppard 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:21:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sheppard GP</AU>
<TI>High-dose propranolol in schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>134</VL>
<PG>470-6</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:21:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheppard-1981" MODIFIED="2010-05-11 09:08:12 +0100" MODIFIED_BY="[Empty name]" NAME="Sheppard 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-05-11 09:08:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Sheppard G</AU>
<TI>Propanolol in the treatment of tardive dyskinesia</TI>
<SO>Proceedings of the 3rd World Congress of Biological Psychiatry; 1981 June 28th- July 3rd; Stockholm, Sweden</SO>
<YR>1981</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shopsin-1975" MODIFIED="2010-05-10 22:22:52 +0100" MODIFIED_BY="[Empty name]" NAME="Shopsin 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-05-10 22:22:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shopsin B, Hirsch J, Gershon S</AU>
<TI>Visual hallucinations and propranolol</TI>
<SO>Biological Psychiatry</SO>
<YR>1975</YR>
<VL>10</VL>
<PG>105-7</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:22:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1986" MODIFIED="2010-05-10 22:23:00 +0100" MODIFIED_BY="[Empty name]" NAME="Silver 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-10 22:23:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver JM, Yudofsky SC, Kogan M, Katz B</AU>
<TI>Elevation of thioridazine plasma levels by propranolol</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<PG>1290-2</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:23:00 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Silver JM, Yudofsky SC</AU>
<TI>Propranolol in the treatment of chronically hospitalized violent patients</TI>
<SO>Biological Psychiatry</SO>
<YR>1985</YR>
<PG>174-5</PG>
<ED>Shagass C et al.</ED>
<PB>Elsevier</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1999" MODIFIED="2010-05-10 22:25:19 +0100" MODIFIED_BY="[Empty name]" NAME="Silver 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-05-10 22:25:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Silver JM, Yudofsky SC, Slater JA, Gold RK, Stryer BLK, Williams DT, Wolland H, Endicott J</AU>
<TI>Propranolol treatment of chronically hospitalized aggressive patients</TI>
<SO>Journal of Neuropsychiatry and Clinical Neurosciences</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>3</NO>
<PG>328-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorgi-1986" MODIFIED="2010-05-10 22:25:28 +0100" MODIFIED_BY="[Empty name]" NAME="Sorgi 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-05-10 22:25:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sorgi PJ, Ratey JJ, Polakoff S</AU>
<TI>B-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1986</YR>
<VL>143</VL>
<PG>775-6</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:25:28 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorgi-1992" MODIFIED="2010-05-10 22:25:37 +0100" MODIFIED_BY="[Empty name]" NAME="Sorgi 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-05-10 22:25:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-05-10 22:25:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sorgi P, Ratey J, Knoedler D, Arnold W, Cole L</AU>
<TI>Depression during treatment with beta-blockers: results from a double-blind placebo-controlled study</TI>
<SO>Journal of Neuropsychiatry and Clinical Neurosciences</SO>
<YR>1992</YR>
<VL>4</VL>
<PG>187-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:25:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stam-1971" MODIFIED="2010-05-10 22:26:27 +0100" MODIFIED_BY="[Empty name]" NAME="Stam 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-05-10 22:26:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stam FC</AU>
<TI>Some experiences with propranolol treatment of schizophrenics</TI>
<TO>Enkele ervaringen met propranolol-behandeling van schizofrenen</TO>
<SO>Nederlands tijdschrift voor psychiatrie</SO>
<YR>1971</YR>
<VL>13</VL>
<PG>424-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staniford-1982" MODIFIED="2010-05-10 22:26:36 +0100" MODIFIED_BY="[Empty name]" NAME="Staniford 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-05-10 22:26:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Staniford DH, Yorkston NJ, Zaki SA</AU>
<TI>Dose dependent changes in propranolol half life when used as an adjunct to neuroleptic treatment</TI>
<SO>Psychopharmacology</SO>
<YR>1982</YR>
<VL>76</VL>
<PG>62-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:26:36 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1996" MODIFIED="2010-02-03 08:55:35 +0000" MODIFIED_BY="[Empty name]" NAME="Stein 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-02-03 08:55:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein D, Meged S, Maoz G, Berger B, Sirota P, Levine J, Elizur A</AU>
<TI>Application of propranolol in the management of aggression in schizophrenic patients</TI>
<SO>Schizophrenia Research</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>2,3</NO>
<PG>136</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiner-1972" NAME="Steiner 1972" YEAR="1972">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Steiner M, Blum I, Wijsenbeek H, Atsmon A</AU>
<TI>Results of the treatment of psychoses with propranolol</TI>
<SO>Kupat Holim Yearbook</SO>
<YR>1972</YR>
<VL>2</VL>
<PG>201-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tress-1983" MODIFIED="2010-05-10 22:26:54 +0100" MODIFIED_BY="[Empty name]" NAME="Tress 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-05-10 22:26:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tress K, Caudrey DJ, Mehta B</AU>
<TI>Tactile-evoked potentials in schizophrenia: interhemispheric transfer and drug effects</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>143</VL>
<PG>156-64</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:26:54 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volk-1972" MODIFIED="2010-05-10 22:27:47 +0100" MODIFIED_BY="[Empty name]" NAME="Volk 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-05-10 22:27:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Volk W, Bier W, Braun JP, Gruter W, Spiegelberg U</AU>
<TI>Treatment of excited psychoses with a beta-receptors blockers (Oxprenolol) in the high dosage</TI>
<TO>Behandlung von erregten psychosen mit einem beta-receptoren-blocker (oxprenolol) in hoher dosierung</TO>
<SO>Nervenarzt</SO>
<YR>1972</YR>
<VL>43</VL>
<PG>491-2</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:27:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Von-Zerssen-1976" MODIFIED="2010-05-10 22:28:03 +0100" MODIFIED_BY="[Empty name]" NAME="Von Zerssen 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-05-10 22:28:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Von Zerssen D</AU>
<TI>Beta-adrenergic blocking agents in the treatment of psychoses. A report on 17 cases</TI>
<SO>Advanced Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>12</VL>
<PG>105-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitman-1987" NAME="Whitman 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Whitman JR, Maier GJ, Eichelman B</AU>
<TI>Beta-adrenergic blockers for aggressive behavior in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>144</VL>
<PG>538</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1979" MODIFIED="2010-05-10 22:28:18 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-05-10 22:28:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wilson JD, King DJ, Sheridan B</AU>
<TI>Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1979</YR>
<VL>7</VL>
<PG>313-4</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:28:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-1993" NAME="Wong 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wong MK, Lee S</AU>
<TI>Nadolol in the treatment of aggression in chronic psychiatric inpatients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>6</NO>
<PG>235</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yorkston-1974" MODIFIED="2010-05-10 22:28:34 +0100" MODIFIED_BY="[Empty name]" NAME="Yorkston 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-05-10 22:28:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston NJ, Zaki SA, Malik MKU, Morrison RC, Havard CWH</AU>
<TI>Propranolol in the control of schizophrenic symptoms</TI>
<SO>British Medical Journal</SO>
<YR>1974</YR>
<VL>4</VL>
<PG>633-5</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:28:34 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yorkston-1975" MODIFIED="2010-05-10 22:28:42 +0100" MODIFIED_BY="[Empty name]" NAME="Yorkston 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-05-10 22:28:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston N</AU>
<TI>Beta-adrenergic blockade in the control of schizophrenic symptoms - a case for controlled studies</TI>
<SO>Scottish Medical Journal</SO>
<YR>1975</YR>
<VL>20</VL>
<PG>292-4</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:28:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yorkston-1976" MODIFIED="2010-05-11 09:02:35 +0100" MODIFIED_BY="[Empty name]" NAME="Yorkston 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-05-11 09:02:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yorkston N, Zaki S, Havard CWH</AU>
<TI>Some practical aspects of using propranolol in the treatment of schizophrenia</TI>
<SO>Propranolol and schizophrenia</SO>
<YR>1978</YR>
<PG>83-97</PG>
<ED>Roberts E, Amacher P</ED>
<PB>Liss</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2010-05-10 22:28:56 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston NJ, Zaki SA, Themen JFA, Havard CWH</AU>
<TI>Propranolol to control schozophrenic symptoms: 55 patients</TI>
<SO>Advanced Clinical Pharmacology</SO>
<YR>1976</YR>
<VL>12</VL>
<PG>91-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-10 22:29:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston NJ, Zaki SA, Themen JFA, Havard CWH</AU>
<TI>Safeguards in the treatment of schizophrenia with propranolol</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1976</YR>
<VL>52</VL>
<PG>175-80</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:29:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yorkston-1978" MODIFIED="2010-05-10 22:29:26 +0100" MODIFIED_BY="[Empty name]" NAME="Yorkston 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-05-10 22:29:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Yorkston NJ, Zaki SA, Havard CW</AU>
<TI>Propranolol in the treatment of schizophrenia: an uncontrolled study with 55 adults</TI>
<SO>Propranolol and schizophrenia</SO>
<YR>1978</YR>
<PG>39-67</PG>
<ED>Roberts E, Amacher P</ED>
<PB>Liss</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2010-05-10 22:29:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yorkston-1981" MODIFIED="2010-05-10 22:30:06 +0100" MODIFIED_BY="[Empty name]" NAME="Yorkston 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-05-10 22:30:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yorkston NJ, Zaki SA, Weller MP, Gruzelier JH, Hirsch SR</AU>
<TI>DL-propranolol and chlorpromazine following admission for schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1981</YR>
<VL>63</VL>
<PG>13-27</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:30:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zubenko-1984" MODIFIED="2010-05-10 22:30:15 +0100" MODIFIED_BY="[Empty name]" NAME="Zubenko 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-05-10 22:30:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zubenko GS, Lipinski JF, Cohen BM, Barreira PJ</AU>
<TI>Comparison of metoprolol and propranolol in the treatment of akathisia</TI>
<SO>Psychiatry Research</SO>
<YR>1984</YR>
<VL>11</VL>
<PG>143-9</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:30:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-02-15 06:48:09 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-02-02 11:16:27 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-05-11 20:35:50 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-05-11 20:35:50 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2010-05-10 22:30:57 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:30:57 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Berlant-1987" MODIFIED="2010-05-10 22:31:11 +0100" MODIFIED_BY="[Empty name]" NAME="Berlant 1987" TYPE="JOURNAL_ARTICLE">
<AU>Berlant JL</AU>
<TI>One more look at propranolol for the treatment of refractory schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>705-14</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:31:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" MODIFIED="2010-03-03 08:36:23 +0000" MODIFIED_BY="[Empty name]" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2010-05-10 22:32:29 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite.</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:32:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-10 22:32:23 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bordeleau-1967" MODIFIED="2010-05-10 22:33:18 +0100" MODIFIED_BY="[Empty name]" NAME="Bordeleau 1967" TYPE="JOURNAL_ARTICLE">
<AU>Bordeleau JM, Albert JM, Killer J, Tetreault L</AU>
<TI>Antiparkinsonian medication and extrapyramidal balance. Study of trihexyphenidyl</TI>
<TO>Medication antiparkinsonienne et bilan extrapyramidal. Etude du trihexyphenidyl</TO>
<SO>Canadian Psychiatric Association Journal</SO>
<YR>1967</YR>
<VL>12</VL>
<PG>585-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brenner-1990" MODIFIED="2010-05-10 22:34:24 +0100" MODIFIED_BY="[Empty name]" NAME="Brenner 1990" TYPE="JOURNAL_ARTICLE">
<AU>Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK</AU>
<TI>Defining treatment-refractoriness in schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1990</YR>
<VL>16</VL>
<PG>551-61</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:33:27 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2010-03-03 08:35:30 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2010-03-03 08:36:12 +0000" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2010-03-03 08:37:05 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-03-03 08:23:33 +0000" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2010-03-03 08:38:48 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2010-03-03 08:36:39 +0000" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-05-11 20:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-05-10 22:36:01 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for systematic reviews of interventions</SO>
<YR>2008</YR>
<PB>John Wiley and Sons, Ltd.</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2010-03-03 08:33:25 +0000" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2010-05-10 22:36:18 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:36:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2010-05-10 22:36:26 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:36:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" MODIFIED="2010-05-11 20:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-1992" MODIFIED="2010-05-10 22:36:33 +0100" MODIFIED_BY="[Empty name]" NAME="Meltzer 1992" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Treatment of the neuroleptic-nonresponsive schizophrenic patient</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1992</YR>
<VL>18</VL>
<PG>515-42</PG>
<IDENTIFIERS MODIFIED="2010-05-10 22:36:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" MODIFIED="2010-05-11 09:35:26 +0100" MODIFIED_BY="[Empty name]" NAME="Mulrow 1997" TYPE="OTHER">
<AU>Mulrow CD, Oxman AD (eds)</AU>
<TI>Cochrane Collaboration Handbook [updated September 1997]</TI>
<SO>The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration</SO>
<YR>1997</YR>
<PB>Update Software; 1996-. Updated quarterly</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-1996" MODIFIED="2010-05-10 22:37:23 +0100" MODIFIED_BY="[Empty name]" NAME="Murray 1996" TYPE="BOOK">
<AU>Murray CL, Lopez AD</AU>
<SO>The Global Burden of Disease</SO>
<YR>1996</YR>
<PB>Harvard University Press</PB>
<CY>Cambridge</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2010-03-03 08:34:41 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rust-1989" MODIFIED="2010-02-03 09:03:53 +0000" MODIFIED_BY="[Empty name]" NAME="Rust 1989" TYPE="BOOK">
<AU>Rust J, Golombok S</AU>
<SO>Modern Psychometrics</SO>
<YR>1989</YR>
<PB>Routledge</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-03-30 05:10:40 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-2010" MODIFIED="2010-05-10 22:41:04 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 2010" TYPE="OTHER">
<AU>Schulz KF, Altman DG, Moher D</AU>
<TI>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010 Mar 24 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2010-03-03 08:37:21 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warner-1995" MODIFIED="2010-03-03 08:24:58 +0000" MODIFIED_BY="[Empty name]" NAME="Warner 1995" TYPE="OTHER">
<AU>Warner R, De Girolamo G</AU>
<TI>Schizophrenia. Epidemiology of mental disorders and psychosocial problems</TI>
<SO>World Health Organization</SO>
<YR>1995</YR>
<PB>Geneva</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2001" MODIFIED="2010-05-10 22:41:42 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2001" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Mental health: New understanding, new hope</TI>
<SO>The World Health Report</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2007" MODIFIED="2010-05-10 22:42:28 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2007" TYPE="CONFERENCE_PROC">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y</AU>
<TI>The Leeds Outcomes Stakeholders Survey (LOSS) Study</TI>
<SO>Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo</SO>
<YR>2007</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-05-10 22:45:36 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Cheine-2001" MODIFIED="2010-05-10 22:45:36 +0100" MODIFIED_BY="[Empty name]" NAME="Cheine 2001" TYPE="COCHRANE_REVIEW">
<AU>Cheine MV, Ahonen J, Wahlbeck K.</AU>
<TI>Beta-blocker supplementation of standard drug treatment for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-05-10 22:45:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-05-10 22:45:36 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858. CD000234 "/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-04-25 14:47:43 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-06-16 10:07:35 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-06-16 10:00:26 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-05-10 16:21:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allan-1996">
<CHAR_METHODS MODIFIED="2010-05-04 13:31:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no further details.<BR/>Blindness: double blind.<BR/>Duration: 3 weeks.<BR/>Setting: Psychiatric Intensive Care Unit.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 16:21:17 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia (DSM-III-R).<BR/>N=34.<BR/>Age: 40.2± 9.0 years (beta-blocker), 38.6 ± 6.9 years (placebo).<BR/>Sex: all male.<BR/>History: newly admitted with aggressive behaviour on neuroleptic medication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-03 09:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>1. Nadolol (80mg/day increasing to 120mg/day) + standard antipsychotic drugs (N=16).<BR/>2. Placebo + standard antipsychotic drugs (N=18).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:21:17 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving study early.<BR/>Global state: relapse.<BR/>Adverse effects: death.<BR/>Adverse effects: specific - low blood pressure.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no SD).<BR/>Adverse effects: Simpson-Angus Neurologic Rating Scale, akathisia scores (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 16:21:17 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-10 16:21:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alpert-1990">
<CHAR_METHODS MODIFIED="2010-05-10 16:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no details.<BR/>Blindness: double blind.<BR/>Duration: 3 weeks.<BR/>Setting: Psychiatric Intensive Care Unit.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 16:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (N=23), schizoaffective disorder (N=4), bipolar disorder (N=3) by DSM-III-R criteria.<BR/>N=32.<BR/>Age: from 21 to 65 years old.<BR/>Sex: all male.<BR/>History: aggression.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-03 09:31:57 +0000" MODIFIED_BY="[Empty name]">
<P>1. Nadolol (80mg/day increasing to 120mg/day) + standard antipsychotic drugs (N=16).<BR/>2. Placebo + standard antipsychotic drugs (N=16).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:21:38 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving study early.<BR/>Global state: relapse.<BR/>Adverse effects: death.<BR/>Adverse effects: specific - low blood pressure.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no SD).<BR/>Adverse effects: Simpson-Angus Neurologic Rating Scale, akathisia scores (modified scales, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 16:21:38 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-11 09:11:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karniol-1982">
<CHAR_METHODS MODIFIED="2010-05-10 16:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, crossover, no details.<BR/>Blindness: double-blind, no details.<BR/>Duration: 4 weeks (1st phase).<BR/>Setting: Americo Bairral Hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 16:21:54 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (ICD-9).<BR/>N=8.<BR/>Age: average 51 years.<BR/>Sex: 4 female, 4 male.<BR/>History: 6 months or more of neuroleptic use with no improvement.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-03 09:32:32 +0000" MODIFIED_BY="[Empty name]">
<P>1. Oxprenolol: increasing dose of 160, 320, 480 and 640mg/day + standard antipsychotic drugs (N=5).<BR/>2. Placebo in matching doses + standard antipsychotic drugs (N=3).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-11 09:11:36 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving study early.<BR/>Adverse effects - death.<BR/>Adverse effects - specific.</P>
<P>Unable to use -<BR/>Movement disorders: Bordeleau scale (<LINK REF="REF-Bordeleau-1967" TYPE="REFERENCE">Bordeleau 1967</LINK>) (no data from phase one).<BR/>Global state: Clinical Global Impression (CGI) (no data from phase one).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 16:21:55 +0100" MODIFIED_BY="[Empty name]">
<P>Only data from phase 1 of study were used.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-10 16:22:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myers-1981">
<CHAR_METHODS MODIFIED="2010-02-05 04:01:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no details.<BR/>Blindness: double-blind, no details.<BR/>Duration: 4 months.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 16:22:11 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (Schneider Ist Rank).<BR/>N=20.<BR/>Age: 38.8 ± 13.4 years (beta-blocker), 43 ± 13.1 years (placebo). Adults &lt; 65 years old.<BR/>Sex: 8 female, 12 male.<BR/>History: all resistant to antipsychotics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-03 09:33:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. Propranolol, gradually increased to 1920mg/day, + standard antipsychotic drug (N=10).<BR/>2. Placebo, in matching doses, + standard antipsychotic drug (N=10).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:22:11 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving the study early.<BR/>Global state: relapse (as defined in trial).<BR/>Adverse effects: death.<BR/>Adverse effect: specific.</P>
<P>Unable to use -<BR/>Global state: Severity of illness (PSE) (no mean, no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 16:22:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-16 10:00:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Poyurovsky-2006">
<CHAR_METHODS MODIFIED="2010-05-11 15:21:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, according to table of random Ns, block design.<BR/>Blindness: double blind.<BR/>Duration: 7 days.<BR/>Settings: Tirat Carmel Mental Health Centre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-15 11:24:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N=90.<BR/>Age: 33.4 ± 10.1 (propranolol), 34.4 ± 11.1 (placebo).<BR/>Sex: 21male, 9 female (propranolol); 16 male, 14 female (placebo).<BR/>History: participants had been receiving FGA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-10 16:22:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Propranolol 40mg/day first dose, then 80mg/day + antipsychotic (N=30).<BR/>2. Placebo in identical doses/capsules + antipsychotic (N=30).<BR/>3. Mirtazapine (not considered for our review) + antipsychotic (N=30).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-16 10:00:26 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving the study early.<BR/>Global state: relapse (as defined in trial).<BR/>Adverse effects: general.<BR/>Adverse effect: specific.<BR/>
</P>
<P>Unable to use -<BR/>Barnes Akathisia Score (BAS) (Akathisia scale not relevant to this review)<BR/>Simpson Angus Scale (SAS) (only mean change scores are given, unable to use/convert this data). <BR/>Brief Psychiatric Scale (BPRS) (only mean change scores are given, unable to use/convert this data).<BR/>Hamilton Rating Scale for Depression (HAM-D) (only mean change scores are given, unable to use/convert this data). </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-03 18:05:44 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-15 11:26:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pugh-1983">
<CHAR_METHODS MODIFIED="2010-03-03 09:34:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised using a manual envelope method, envelopes held in pharmacy with no possibility of researchers knowing treatment allocation before randomisation.<BR/>Double-blind: no further details.<BR/>Duration: 12 weeks.<BR/>Setting: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-15 11:26:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (Feighner criteria &amp; PSE).<BR/>N=41.<BR/>Age: mean 45 years, range 30-66 years.<BR/>Sex: male and female*.<BR/>History: age at onset: mean 25 years, range 14-47; all resistant to antipsychotic treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-03 09:34:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. Propranolol 80-640mg/day + standard antipsychotic drugs (N=21).<BR/>2. Placebo, matching dose, + standard antipsychotic drugs (N=20).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:22:52 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving the study early.<BR/>Global state: relapse (as defined in trial).<BR/>Adverse effects: death.<BR/>Adverse effect: specific.</P>
<P>Unable to use -<BR/>Global state: Global scores (no SD).<BR/>Behaviour: NOSIE (no SD).<BR/>Mental state: BPRS, CPRS (no data).<BR/>Adverse effects: general (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-15 11:26:55 +0100" MODIFIED_BY="[Empty name]">
<P>* numbers not provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-11 15:23:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratey-1992">
<CHAR_METHODS MODIFIED="2010-05-11 15:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no details.<BR/>Blindness: double blind.<BR/>Duration: 4 weeks (lead in placebo) + 13 weeks<BR/>Settings: Veterans Administration Hospital (Massachusettts), State Hospital (Ohio).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 16:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic psychiatric patients (schizophrenia N=29, schizoaffective N=6, mentally retarded N=4, bipolar N=1, infantile autism-residual type N=1).<BR/>N=48.<BR/>Age: 39.85 ± 8.91 years old (nadolol), 43.75 ± 12.92 years old (placebo), completer data only.<BR/>Sex: 21 male, 20 female (completer data only)<BR/>History: eight aggressive incidents in two months prior to the start of the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-10 16:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>1. Nadolol 40/80/120mg/day + concomitant antipsychotic medication (N=23).<BR/>2. Placebo + concomitant antipsychotic medication (N=25).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving the study early.<BR/>Global state: relapse (as defined in trial).<BR/>Adverse effects: death.<BR/>Adverse effect: specific.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no ITT analysis).<BR/>Global state: OAS (no ITT analysis), frequency of PRN medication by month (no ITT analysis).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 16:23:11 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-15 11:29:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wells-1991">
<CHAR_METHODS MODIFIED="2010-02-20 08:53:00 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double blind, no details.<BR/>Duration: 15 days.<BR/>Settings: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-15 11:29:24 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia (N=14), bipolar disorder (N=5), schizoaffective disorder (N=1)- completer data.<BR/>N=25.<BR/>Age: 18 - 65 years old.<BR/>Sex: male and female*.<BR/>History: psychiatric inpatients with neuroleptic- induced akathisia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-20 08:55:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Nadolol 40/80/day + neuroleptic (N=13).<BR/>2. Placebo + neuroleptic (N=12).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:23:30 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving the study early.<BR/>Global state: relapse (as defined in trial).<BR/>Adverse effects: general.<BR/>Adverse effect: specific.</P>
<P>Unable to use -<BR/>Adverse effects: ESRS, number of side effects reported (no ITT analysis).<BR/>Global state: response (no ITT analysis), PRN medication (no ITT analysis).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-15 11:29:34 +0100" MODIFIED_BY="[Empty name]">
<P>* numbers not given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-10 16:23:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yorkston-1977">
<CHAR_METHODS MODIFIED="2010-05-10 16:23:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no details.<BR/>Blindness: double blind, no details.<BR/>Duration: 12 weeks.<BR/>Settings: hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-10 16:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (modified BPRS &amp; PSE).<BR/>N=14.<BR/>Age: mean 40 years, range 27-55 years.<BR/>Sex: 9 female, 5 male.<BR/>History: age of onset, mean 30 years; all resistant to antipsychotics. Chronic schizophrenia, mean duration of treatment is 10 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-16 15:02:01 +0000" MODIFIED_BY="[Empty name]">
<P>1. Propranolol: mean ~450mg/day + standard antipsychotic drug (N=7).<BR/>2. Placebo + standard antipsychotic drug (N=7).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-10 16:23:49 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: leaving the study early.<BR/>Global state: relapse (as defined in trial).<BR/>Adverse effects: death.<BR/>Adverse effect: specific.</P>
<P>Unable to use -<BR/>Mental state: BPRS (modified scale, no SD).<BR/>Behaviour: visual analogue scale (unpublished scale, no SD).<BR/>Global state: severity of illness (unpublished scale, no SD), global ratings of clinical change (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-10 16:23:49 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BPRS - Brief Psychiatric Rating Scale<BR/>CGI - Clinical Global Impression Scale<BR/>CPRS - Comprehensive Psychopathological Rating Scale<BR/>DSM-III-R - Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised<BR/>ESRS - Extrapyramidal Symptom Rating Scale<BR/>ICD-9 - International Classification of Diseases, 9th edition.<BR/>NOSIE - Nurses Observation Scale for In-patient Evaluation<BR/>PSE - Present State Examination<BR/>PRN - as required<BR/>FGA - First generation antipsychotics<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-06-16 10:07:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-06-15 11:31:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-15 11:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over.<BR/>Participants: schizophrenia.<BR/>Intervention: propranolol versus lorazepam versus no treatment (not placebo).<BR/>Outcomes: measured at 3-4 days, not relevant due to short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:24:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:24:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over study.<BR/>Participants: schizophrenia, bipolar disorder.<BR/>Interventions: propranolol + standard neuroleptics versus placebo + standard neuroleptics for 6-10 days each phase.<BR/>Outcomes: not possible to extract data from first phase.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:24:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia, post traumatic stress disorder.<BR/>Interventions: propranolol + neuroleptics versus placebo + neuroleptics - the study was designed for assessment of akathisia.<BR/>Outcomes: measured at 3 days, not relevant due to short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:25:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:25:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: chronic schizophrenia, paranoid disorder, major depression with psychosis.<BR/>Interventions: propranolol versus metoprolol - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:25:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:25:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, parallel-group study.<BR/>Participants: schizophrenia, schizoaffective disorder, bipolar disorder, personality disorder - all suffered from akathisia.<BR/>Interventions: d-propranolol + standard neuroleptics versus placebo + standard neuroleptics - the study was designed for assessment of akathisia.<BR/>Outcomes: measured at 6 days, not relevant due to the short duration.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:26:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adler-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:26:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, parallel-group study.<BR/>Participants: schizophrenia, schizoaffective disorder, major depression with akathisia.<BR/>Interventions: propranolol + standard neuroleptics versus benztropine + standard neuroleptics versus placebo + standard neuroleptics for 12 days (phase A); thereafter propranolol or benztropine (phase B).<BR/>Outcomes: no data were possible to extract from phase A.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ananth-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:26:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aoba-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:26:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Intervention: carteolol + neuroleptic versus placebo + neuroleptic.<BR/>Outcome: only completer data are available - unclear how many started study.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1971a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1971b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1978a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atsmon-1978b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Auriol-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Auriol-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bacher-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Belmaker-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case-series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:27:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bigelow-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:27:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over.<BR/>Participants: schizophrenia.<BR/>Interventions: propranolol + neuroleptics versus placebo + neuroleptics.<BR/>Outcomes: no outcome data reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-25 14:53:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlsson-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-25 14:53:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:27:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caspi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, crossover.<BR/>Participants: schizophrenia.<BR/>Intervention: pindolol + standard antipsychotic versus placebo + standard antipsychotic.<BR/>Outcome: no data available for the first phase of the trial.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Christison-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daskalopoulos-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-03 08:27:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Degwitz-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-03 08:27:56 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dominguez-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dupuis-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: historical controls.<BR/>Participants: 16 persons (10 with schizophrenia).<BR/>Interventions: propranolol for 6 month, then sotalol, then betaxolol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eccleston-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: propranolol versus thioridazine - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elizur-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: controlled trial, unsure if randomised.<BR/>Participants: chronic schizophrenia.<BR/>Interventions: propranolol versus chlorpromazine versus perphenazine versus trifluzine versus haloperidol - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elizur-1979a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elizur-1979b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, open trial.<BR/>Participants: chronic schizophrenia.<BR/>Interventions: propranolol versus standard neuroleptics (four different subgroups) versus propranolol + haloperidol - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fava-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:28:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Floru-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:28:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: controlled, unclear if randomised.<BR/>Participants: schizoaffective, manic, depressed, cyclothymic.<BR/>Intervention: lithium + pindolol versus lithium + practolol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:28:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Floru-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:28:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over study.<BR/>Participants: schizophrenia.<BR/>Interventions: bupranolol + standard neuroleptics versus placebo + standard neuroleptics. Outcomes: no data were possible to extract before first crossover.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gardos-1973a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gardos-1973b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gershon-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gilligan-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greendyke-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: inadequate randomisation (category C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gruzelier--1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gruzelier-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: controlled open trial, unclear if randomised. <BR/>Participants: schizophrenia.<BR/>Interventions: D-propranolol (+ haloperidol in the phase II) versus DL-propranolol versus chlorpromazine - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:29:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gruzelier-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:29:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: both those with schizophrenia and normal controls.<BR/>Interventions: propranolol versus propranolol + standard neuroleptics versus standard neuroleptics - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanssen-1978a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanssen-1978b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hanssen-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hayes-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:29:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hebenstreit-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:29:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: &#8220;psychiatric patients&#8221;, not schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hinshelwood-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hirsch-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:30:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Irwin-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:30:11 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Intervention: propranolol + neuroleptics versus placebo + neuroleptics - the study was designed for assessment of akathisia.<BR/>Outcomes: measured at 2 days, not relevant due to the short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jefferson-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-King-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: cross-over trial, unclear if randomised.<BR/>Participants: schizophrenia.<BR/>Intervention: propranolol versus placebo - no neuroleptic medication used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-King-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:30:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramer-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:30:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, cross-over study.<BR/>Participants: schizophrenia and akathisia.<BR/>Interventions: propranolol + standard neuroleptics versus placebo + standard neuroleptics - the study was designed for assessment of akathisia.<BR/>Outcomes: measured at 2 days, not relevant due to the short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:30:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramer-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, cross-over study.<BR/>Participants: schizophrenia + akathisia.<BR/>Interventions: propranolol + standard neuroleptics versus placebo + standard neuroleptics - the study was designed for assessment of akathisia.<BR/>Outcomes: measured at 2 days, not relevant due to the short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-02 11:18:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kugler-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-02 11:18:55 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lader-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-16 10:07:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindstr_x00f6_m-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-16 10:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over study.<BR/>Participants: chronic schizophrenia with persistent psychotic symptoms.<BR/>Interventions:propranolol versus placebo.<BR/>Outcomes: data from each arm, in phase one, are not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lipinski-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malas-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:31:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manchanda-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:31:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: D-propranolol versus placebo (four weeks) - standard neuroleptics given only during the first week of the trial.<BR/>Outcomes: no data were possible to extract from first week of trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:32:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maoz-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:32:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia - number unclear.<BR/>Intervention: propranolol + haloperidol versus placebo + haloperidol.<BR/>Outcome: only completer data are available - unclear how many started study.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:32:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marsden-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:32:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: unsure if randomised.<BR/>Participants: healthy persons, no people with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-May-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: individual psychotherapy versus drug therapy versus individual psychotherapy + drugs versus electroshock therapy versus control (no specific treatment) - no beta-blockers, no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-May-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:33:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Metzer-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:33:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over study.<BR/>Participants: schizophrenia.<BR/>Interventions: long-acting propranolol + standard neuroleptics versus placebo + standard neuroleptics for 2 weeks.<BR/>Outcomes: no data from first phase.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-M_x00f6_ller-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orzack-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peet-1981a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peet-1981b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, cross-over trial.<BR/>Participants: chronic schizophrenia.<BR/>Interventions: chlorpromazine versus chlorpromazine + propranolol - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-16 10:07:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peet-1981c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-16 10:07:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: chlorpromazine versus propranolol versus placebo. No adjunct drug, monotherapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Peters-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poli-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rackensperger-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:34:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratey-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:34:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with "chronic mental illness", not schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ratey-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, guideline paper including case reports.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-02 06:27:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reiter-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-02 06:27:36 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Remington-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ridges-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ritrovato-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-15 11:47:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sachdev-1993a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-15 11:47:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over.<BR/>Participants: schizophrenia, bipolar disorder.<BR/>Interventions: propranolol + neuroleptics versus benztropine + neuroleptics versus placebo + neuroleptics - study was designed for assessment of akathisia.<BR/>Outcomes: measured at 1 day, not relevant due to the short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-06-15 11:47:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sachdev-1993b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-06-15 11:47:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised cross-over.<BR/>Participants: schizophrenia, bipolar disorder.<BR/>Interventions: propranolol + neuroleptics versus benztropine + neuroleptics versus placebo + neuroleptics - study designed for assessment of akathisia.<BR/>Outcomes: measured at 3 days, not relevant due to the short duration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:35:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scharbach-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:35:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: controlled trial.<BR/>Participants: non-psychotic people with anxiety - no people with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scheinin-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schoenen-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schrodt-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sethi-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheppard-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheppard-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shopsin-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sorgi-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:36:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sorgi-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:36:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with "chronic mental illness", not schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stam-1971">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Staniford-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:36:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not clear.<BR/>Participants: people with schizophrenia.<BR/>Intervention: propranolol + haloperidol versus placebo + haloperidol.<BR/>Outcome: no data available.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Steiner-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-02 11:19:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tress-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-02 11:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Volk-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Von-Zerssen-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whitman-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wong-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yorkston-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yorkston-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: propranolol versus chlorpromazine - no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yorkston-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yorkston-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:37:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yorkston-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:37:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Interventions: beta-blockers versus neuroleptics - not adjunct to neuroleptics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-10 16:37:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zubenko-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-10 16:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: historical controls.<BR/>Participants: 5 people, 1 with schizophrenia.<BR/>Intervention: propranolol or metoprolol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-02-15 06:48:09 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-02-02 11:16:27 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-05-11 15:21:00 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-02-20 09:34:21 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-04 10:20:36 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allan-1996">
<DESCRIPTION>
<P>Randomised, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-04 10:20:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alpert-1990">
<DESCRIPTION>
<P>Randomised, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-04 10:21:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karniol-1982">
<DESCRIPTION>
<P>Randomised, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 05:35:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1981">
<DESCRIPTION>
<P>Randomised, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-20 09:34:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poyurovsky-2006">
<DESCRIPTION>
<P>Randomised using block design according to a table of random Ns.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 06:06:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pugh-1983">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 14:15:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ratey-1992">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-16 14:49:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1991">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-18 05:55:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yorkston-1977">
<DESCRIPTION>
<P>Randomised, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-05-11 15:21:00 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-04 09:05:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allan-1996">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-04 10:17:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alpert-1990">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 15:21:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karniol-1982">
<DESCRIPTION>
<P>No details. According to the authors of previous review - adequate allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 05:35:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1981">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 05:30:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Poyurovsky-2006">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 13:56:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pugh-1983">
<DESCRIPTION>
<P>No details. According to the authors of previous review - adequate allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 14:15:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ratey-1992">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-16 14:49:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1991">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-20 08:00:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yorkston-1977">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-03-30 03:54:30 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-20 03:51:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allan-1996">
<DESCRIPTION>
<P>Double-blind, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-05 03:15:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alpert-1990">
<DESCRIPTION>
<P>Double blind, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 03:54:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karniol-1982">
<DESCRIPTION>
<P>Double blind, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-20 05:39:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Myers-1981">
<DESCRIPTION>
<P>Double blind, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-05 05:31:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poyurovsky-2006">
<DESCRIPTION>
<P>Double blind, explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 03:54:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pugh-1983">
<DESCRIPTION>
<P>Double blind, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-05 14:15:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ratey-1992">
<DESCRIPTION>
<P>Double blinded, no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-16 14:49:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wells-1991">
<DESCRIPTION>
<P>No details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-18 05:59:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yorkston-1977">
<DESCRIPTION>
<P>Blinding implied, but no details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-03-30 05:31:37 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-20 03:51:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allan-1996">
<DESCRIPTION>
<P>Two participants left the study, reasons were explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-04 10:17:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alpert-1990">
<DESCRIPTION>
<P>Two participants left the study, reason explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-05 03:43:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Karniol-1982">
<DESCRIPTION>
<P>All participants completed the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-05 04:54:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Myers-1981">
<DESCRIPTION>
<P>3 participants left the study, reasons explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 05:30:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poyurovsky-2006">
<DESCRIPTION>
<P>Seventeen participants have left the study. Reasons explained. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 05:31:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pugh-1983">
<DESCRIPTION>
<P>Three participants left the study, reasons explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 05:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ratey-1992">
<DESCRIPTION>
<P>Seven participants left the study, reasons explained.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 05:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wells-1991">
<DESCRIPTION>
<P>Five patients have left the study, the reasons explained but the data not included in final analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-20 08:02:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yorkston-1977">
<DESCRIPTION>
<P>The trial code was broken for one participant due to suspected adverse event.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-11 15:20:56 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-20 03:57:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allan-1996">
<DESCRIPTION>
<P>Data presented in graphs, no tables. Methods described are consistent with outcomes reported, no protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-04 10:17:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alpert-1990">
<DESCRIPTION>
<P>Data presented in graphs, no tables.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 15:20:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karniol-1982">
<DESCRIPTION>
<P>Data from the first phase of the trial were not reported. The reported data were presented in graphs, no tables. The outcome on Index of Parkinsonism was described in methodology, but not reported in results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 05:35:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1981">
<DESCRIPTION>
<P>Methods described are consistent with outcomes reported, no protocol available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-11 13:56:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poyurovsky-2006">
<DESCRIPTION>
<P>Methods described are consistent with outcomes reported, no protocol available. Authors conducted Intention to Treat (ITT) analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 06:53:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pugh-1983">
<DESCRIPTION>
<P>The adverse effects are stated, but the data are not reported. The number of outcomes are reported without SD.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 14:16:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ratey-1992">
<DESCRIPTION>
<P>Only completer data available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-16 14:50:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1991">
<DESCRIPTION>
<P>Protocol is not available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-20 08:03:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yorkston-1977">
<DESCRIPTION>
<P>Only completer data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-04-25 16:37:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allan-1996">
<DESCRIPTION>
<P>Authors did declare the sources of support. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:35:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alpert-1990">
<DESCRIPTION>
<P>Authors did declare sources of support. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:34:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karniol-1982">
<DESCRIPTION>
<P>Authors did not state the interests or source of support for the study. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:33:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myers-1981">
<DESCRIPTION>
<P>Sources of support were stated. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:37:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Poyurovsky-2006">
<DESCRIPTION>
<P>The funding source for the study was stated, sequence generation explained, blinding described. The role of funding sources was described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:33:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pugh-1983">
<DESCRIPTION>
<P>The funding source for the study was mentioned. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:32:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ratey-1992">
<DESCRIPTION>
<P>Source of financial support was given. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:32:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1991">
<DESCRIPTION>
<P>Sources of support were stated. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 16:27:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yorkston-1977">
<DESCRIPTION>
<P>Sources of funding are stated. Declaration of interests by authors was not made.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-06-03 18:31:48 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-06-03 18:31:48 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-06-03 18:31:48 +0100" MODIFIED_BY="Grade Profiler">Beta-blockers compared to Placebo for People with Schizophrenia</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Beta-blockers compared to Placebo for People with Schizophrenia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> People with Schizophrenia<BR/>
<B>Settings:</B> Hospital<BR/>
<B>Intervention:</B> Beta-blockers <BR/>
<B>Comparison: </B>Placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Beta-blockers </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Global state: 1. Leaving the study early - Short term</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.62 </B>
<BR/>(0.92 to 2.83)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>274<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>109 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>177 per 1000</B>
<BR/>(100 to 308)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>59 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>96 per 1000</B>
<BR/>(54 to 167)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Global state: 2. Relapse - short term</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 3.12 </B>
<BR/>(0.34 to 28.36)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>68<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Death - short term</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>282<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>-2147483648 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 1. Death - medium term</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>20<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Risks were calculated from pooled risk differences</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>-2147483648 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effect: 2. General - Short term</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 5.42 </B>
<BR/>(0.27 to 107.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse effects: 3. Specific - cardiovascular - short term</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.63 </B>
<BR/>(0.7 to 3.84)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>274<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>254 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>414 per 1000</B>
<BR/>(178 to 975)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>86 per 1000</B>
<BR/>(37 to 204)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Lack of allocation concealment in majority of studies<BR/>
<SUP>2</SUP> Although blinding was stated (implied in some cases), no details were given<BR/>
<SUP>3</SUP> Small sample size<BR/>
<SUP>4</SUP> Clinical parameters for this outcome differ widely between studies<BR/>
<SUP>5</SUP> No details on allocation concealment and blinding</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-06-16 10:00:55 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-06-16 10:00:55 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-05-10 16:42:14 +0100" MODIFIED_BY="[Empty name]">Suggested design for future study</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised, clearly described.<BR/>Blinding: double, tested.<BR/>Duration: 1 year.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia.<BR/>N=200-300.*<BR/>Age: adults.<BR/>Sex: both.<BR/>History: people with residual symptoms.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Propranolol (80-360 mg/day)** + standard antipsychotic treatment. N=150.<BR/>2. No adjunctive treatment + standard antipsychotic treatment. N=150.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Relapse.<BR/>Adverse effects: list, consequences of low blood pressure, impotence.<BR/>Service outcomes: admitted, ready for discharge.<BR/>Social functioning: working, trouble with family, trouble with police.<BR/>Satisfaction with treatment: binary outcome, family, clinician and patient.<BR/>Healthy days.<BR/>Compliance: attending follow up, taking medication.<BR/>Quality of life.<BR/>Cost.</P>
</TD>
</TR>
<TR>
<TH>
<P>Notes</P>
</TH>
<TD>
<P>* Powered to be able to identify a difference of ~20% between groups for primary outcome with adequate degree of certainty.<BR/>** Expert consensus document on beta-adrenergic receptor blockers, 2004<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-06-03 17:54:06 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-06-03 17:54:06 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>BETA-BLOCKERS versus PLACEBO</NAME>
<DICH_OUTCOME CHI2="6.999859098442037" CI_END="2.8265927884002866" CI_START="0.922831856670367" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6150758096666875" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.45126324659033534" LOG_CI_START="-0.03487742180444384" LOG_EFFECT_SIZE="0.20819291239294574" METHOD="MH" MODIFIED="2010-05-10 14:58:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4288946106151079" P_Q="0.0" P_Z="0.09320375554446104" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="138" WEIGHT="100.0" Z="1.6787347229107425">
<NAME>Global state: 1. Leaving the study early - short term</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Allan-1996" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="5.6952750053827295"/>
<DICH_DATA CI_END="14.640493479420055" CI_START="0.06830370857414654" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1655557155049627" LOG_CI_START="-1.1655557155049627" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="1.3693063937629153" STUDY_ID="STD-Alpert-1990" TOTAL_1="16" TOTAL_2="16" VAR="1.875" WEIGHT="6.05122969321915"/>
<DICH_DATA CI_END="120.15725297777159" CI_START="0.4077989366906108" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.079749990979728" LOG_CI_START="-0.3895539109512146" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="1.4504813352456845" STUDY_ID="STD-Myers-1981" TOTAL_1="10" TOTAL_2="10" VAR="2.103896103896104" WEIGHT="3.025614846609575"/>
<DICH_DATA CI_END="1.9917413161804456" CI_START="0.39669983766031425" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.29923293235542303" LOG_CI_START="-0.4015379772501856" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.4116363011742823" STUDY_ID="STD-Poyurovsky-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.16944444444444445" WEIGHT="54.46106723897235"/>
<DICH_DATA CI_END="19.40224594904089" CI_START="0.1869947388236024" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.287852005539399" LOG_CI_START="-0.7281706123513129" LOG_EFFECT_SIZE="0.2798406965940431" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="1.1842216652219095" STUDY_ID="STD-Pugh-1983" TOTAL_1="21" TOTAL_2="20" VAR="1.4023809523809523" WEIGHT="6.1988206613464465"/>
<DICH_DATA CI_END="269.48888898529077" CI_START="0.979864145769709" EFFECT_SIZE="16.25" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.4305408639500237" LOG_CI_START="-0.008834133320237407" LOG_EFFECT_SIZE="1.2108533653148932" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="1.4329009484975326" STUDY_ID="STD-Ratey-1992" TOTAL_1="23" TOTAL_2="25" VAR="2.0532051282051285" WEIGHT="2.9045902527451917"/>
<DICH_DATA CI_END="6.9129858840241205" CI_START="0.27732730768974334" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8396656700754479" LOG_CI_START="-0.5570073644825093" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.820412654142367" STUDY_ID="STD-Wells-1991" TOTAL_1="13" TOTAL_2="12" VAR="0.673076923076923" WEIGHT="12.586557761895833"/>
<DICH_DATA CI_END="7.016577384170804" CI_START="0.015835514243992307" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8461253193035242" LOG_CI_START="-1.8003678287428493" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-10 14:57:43 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Yorkston-1977" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="9.076844539828725"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0012638180247382886" CI_END="28.36205868167787" CI_START="0.3437581079561225" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.122448979591837" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.4527377512516277" LOG_CI_START="-0.46374704967345753" LOG_EFFECT_SIZE="0.49449535078908513" METHOD="MH" MODIFIED="2010-05-10 15:03:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9716410062253077" P_Q="0.0" P_Z="0.31181169748186544" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="33" TOTAL_2="35" WEIGHT="100.0" Z="1.0114278783753239">
<NAME>Global state: 2. Relapse - short term</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516804" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-05-10 14:58:14 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Myers-1981" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="51.02040816326531"/>
<DICH_DATA CI_END="76.00582420414608" CI_START="0.13896961332370927" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8808468728440408" LOG_CI_START="-0.857080150886292" LOG_EFFECT_SIZE="0.5118833609788743" MODIFIED="2010-05-10 14:58:14 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Ratey-1992" TOTAL_1="23" TOTAL_2="25" VAR="2.5865384615384617" WEIGHT="48.97959183673469"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.04036547424779081" CI_START="-0.04036547424779081" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-1.3939899406910639" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-04-18 06:15:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="151" TOTAL_2="151" WEIGHT="200.0" Z="0.0">
<NAME>Adverse effects: 1. Death</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.04103550018211014" CI_START="-0.04103550018211014" DF="8" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-1.386840268588816" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-20 10:38:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="9" TAU2="0.0" TOTAL_1="141" TOTAL_2="141" WEIGHT="99.99999999999999" Z="0.0">
<NAME>short term</NAME>
<DICH_DATA CI_END="0.10784810222656298" CI_START="-0.10784810222656298" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="133" O_E="0.0" SE="0.05502555305977816" STUDY_ID="STD-Allan-1996" TOTAL_1="16" TOTAL_2="18" VAR="0.0030278114895344616" WEIGHT="12.04771724513695"/>
<DICH_DATA CI_END="0.11358387504551336" CI_START="-0.11358387504551336" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-20 04:39:48 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.0579520215378693" STUDY_ID="STD-Alpert-1990" TOTAL_1="16" TOTAL_2="16" VAR="0.0033584368003256666" WEIGHT="11.37839962040712"/>
<DICH_DATA CI_END="0.3923612512288847" CI_START="-0.3923612512288847" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="129" O_E="0.0" SE="0.20018799035277188" STUDY_ID="STD-Karniol-1982" TOTAL_1="5" TOTAL_2="3" VAR="0.04007523148148148" WEIGHT="2.6668124110329186"/>
<DICH_DATA CI_END="0.17408193796294572" CI_START="-0.17408193796294572" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-20 06:58:35 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.08881894735621768" STUDY_ID="STD-Myers-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.007888805409466567" WEIGHT="7.11149976275445"/>
<DICH_DATA CI_END="0.0627126957943536" CI_START="-0.0627126957943536" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-20 10:38:25 +0000" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.03199686131430135" STUDY_ID="STD-Poyurovsky-2006" TOTAL_1="30" TOTAL_2="30" VAR="0.0010237991339666342" WEIGHT="21.33449928826335"/>
<DICH_DATA CI_END="0.09016625069010467" CI_START="-0.09016625069010467" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="132" O_E="0.0" SE="0.04600403446253327" STUDY_ID="STD-Pugh-1983" TOTAL_1="21" TOTAL_2="20" VAR="0.002116371186829949" WEIGHT="14.569901952960336"/>
<DICH_DATA CI_END="0.07779334067637168" CI_START="-0.07779334067637168" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-20 08:37:21 +0000" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.03969120927220889" STUDY_ID="STD-Ratey-1992" TOTAL_1="23" TOTAL_2="25" VAR="0.0015753920934902814" WEIGHT="17.0379681815992"/>
<DICH_DATA CI_END="0.14275079685492442" CI_START="-0.14275079685492442" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-20 09:28:10 +0000" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.0728333775421" STUDY_ID="STD-Wells-1991" TOTAL_1="13" TOTAL_2="12" VAR="0.005304700884190076" WEIGHT="8.875151703917554"/>
<DICH_DATA CI_END="0.2372158709778113" CI_START="-0.2372158709778113" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="130" O_E="0.0" SE="0.12103072956898178" STUDY_ID="STD-Yorkston-1977" TOTAL_1="7" TOTAL_2="7" VAR="0.0146484375" WEIGHT="4.9780498339281145"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.17408193796294572" CI_START="-0.17408193796294572" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.7592462871822322" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-01-12 13:37:09 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>medium term</NAME>
<DICH_DATA CI_END="0.17408193796294572" CI_START="-0.17408193796294572" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-12 13:37:09 +0000" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.08881894735621768" STUDY_ID="STD-Myers-1981" TOTAL_1="10" TOTAL_2="10" VAR="0.007888805409466567" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="107.20322514518227" CI_START="0.2736883870615186" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="2.0302078510441275" LOG_CI_START="-0.5627436298536661" LOG_EFFECT_SIZE="0.7337321105952308" METHOD="MH" MODIFIED="2010-05-10 14:59:19 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.2673314155616149" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="25" WEIGHT="100.0" Z="1.1092290169419468">
<NAME>Adverse effects: 2. General - short term</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="107.20322514518227" CI_START="0.2736883870615186" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0302078510441275" LOG_CI_START="-0.5627436298536661" LOG_EFFECT_SIZE="0.7337321105952308" MODIFIED="2010-05-10 14:58:34 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="1.5231125351961998" STUDY_ID="STD-Ratey-1992" TOTAL_1="23" TOTAL_2="25" VAR="2.319871794871795" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.851410660171541" CI_END="3.837793195058173" CI_START="0.6954560927445247" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6337125390339278" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5840815684544537" LOG_CI_START="-0.1577302837606498" LOG_EFFECT_SIZE="0.21317564234690195" METHOD="MH" MODIFIED="2010-06-03 17:54:06 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5572029604359767" P_Q="0.0" P_Z="0.2599641607427864" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="138" WEIGHT="99.99999999999999" Z="1.1264758850468326">
<NAME>Adverse effects: 3. Specific - cardiovascular - short term</NAME>
<GROUP_LABEL_1>Beta-blocker</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Beta-blocker</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03872140332672795" CI_END="34.94399029535678" CI_START="0.4911650089487075" DF="1" EFFECT_SIZE="4.142857142857143" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="1.5433724960763995" LOG_CI_START="-0.3087725803070007" LOG_EFFECT_SIZE="0.6172999578846993" MODIFIED="2010-05-10 15:14:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.844001707342403" P_Z="0.1913928861249924" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="35" WEIGHT="12.232239175448626" Z="1.3064696718840103">
<NAME>collapse</NAME>
<DICH_DATA CI_END="92.62160011346378" CI_START="0.2699154405600246" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9667122795130358" LOG_CI_START="-0.5687722708409984" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2010-05-10 15:12:37 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.4893561757289013" STUDY_ID="STD-Myers-1981" TOTAL_1="10" TOTAL_2="10" VAR="2.2181818181818183" WEIGHT="6.240938354820727"/>
<DICH_DATA CI_END="76.00582420414608" CI_START="0.13896961332370927" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8808468728440408" LOG_CI_START="-0.857080150886292" LOG_EFFECT_SIZE="0.5118833609788743" MODIFIED="2010-05-10 15:12:44 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="1.6082718866965442" STUDY_ID="STD-Ratey-1992" TOTAL_1="23" TOTAL_2="25" VAR="2.5865384615384617" WEIGHT="5.991300820627898"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.382590940745529" CI_START="0.013713297978184326" DF="0" EFFECT_SIZE="0.3181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.8682088054265786" LOG_CI_START="-1.8628580870424774" LOG_EFFECT_SIZE="-0.4973246408079494" MODIFIED="2010-05-10 15:14:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.47534153044019734" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="20" WEIGHT="19.158229368286886" Z="0.7138150935048501">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="7.382590940745529" CI_START="0.013713297978184326" EFFECT_SIZE="0.3181818181818182" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8682088054265786" LOG_CI_START="-1.8628580870424774" LOG_EFFECT_SIZE="-0.4973246408079494" MODIFIED="2010-05-10 15:12:17 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="1.6042422116354729" STUDY_ID="STD-Pugh-1983" TOTAL_1="21" TOTAL_2="20" VAR="2.5735930735930737" WEIGHT="19.158229368286886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40429127311266483" CI_END="3.531019801989328" CI_START="0.15659093909933608" DF="2" EFFECT_SIZE="0.7435897435897435" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="0.5479001530971049" LOG_CI_START="-0.8052333713521912" LOG_EFFECT_SIZE="-0.12866660912754316" MODIFIED="2010-05-10 15:14:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8169760174309311" P_Z="0.7093436962923639" STUDIES="3" TAU2="0.0" TOTAL_1="39" TOTAL_2="41" WEIGHT="42.95234044200148" Z="0.3727376719980554">
<NAME>hypotension</NAME>
<DICH_DATA CI_END="16.55254127889542" CI_START="0.0764610689485897" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2188646796026918" LOG_CI_START="-1.1165596347079294" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2010-05-10 15:11:08 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="1.3718398027628607" STUDY_ID="STD-Allan-1996" TOTAL_1="16" TOTAL_2="18" VAR="1.8819444444444444" WEIGHT="11.74764866789784"/>
<DICH_DATA CI_END="14.640493479420055" CI_START="0.06830370857414654" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1655557155049627" LOG_CI_START="-1.1655557155049627" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-10 15:11:15 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.3693063937629153" STUDY_ID="STD-Alpert-1990" TOTAL_1="16" TOTAL_2="16" VAR="1.875" WEIGHT="12.481876709641455"/>
<DICH_DATA CI_END="7.016577384170804" CI_START="0.015835514243992307" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8461253193035242" LOG_CI_START="-1.8003678287428493" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2010-05-10 15:11:17 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="1.5545631755148024" STUDY_ID="STD-Yorkston-1977" TOTAL_1="7" TOTAL_2="7" VAR="2.4166666666666665" WEIGHT="18.722815064462182"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.941971024429275" CI_START="0.013800833844593588" DF="0" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.8414827966075427" LOG_CI_START="-1.86009467278967" LOG_EFFECT_SIZE="-0.5093059380910636" MODIFIED="2010-05-10 15:13:21 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.4599122083836975" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="19.416252659442264" Z="0.7389914278442651">
<NAME>increase creatinine phosphokinase (CPK )</NAME>
<DICH_DATA CI_END="6.9419710244292725" CI_START="0.013800833844593588" EFFECT_SIZE="0.30952380952380953" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8414827966075425" LOG_CI_START="-1.86009467278967" LOG_EFFECT_SIZE="-0.5093059380910636" MODIFIED="2010-05-10 15:13:20 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.5869199785480734" STUDY_ID="STD-Wells-1991" TOTAL_1="13" TOTAL_2="12" VAR="2.518315018315018" WEIGHT="19.416252659442264"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="190.5337733482898" CI_START="0.63505801556145" DF="0" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="2.279971968351581" LOG_CI_START="-0.19718659803513053" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-05-10 15:14:57 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.09936700350020851" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="6.240938354820727" Z="1.6479301602810232">
<NAME>unspecified - including palpitation, dizziness, hypotension</NAME>
<DICH_DATA CI_END="190.5337733482898" CI_START="0.63505801556145" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.279971968351581" LOG_CI_START="-0.19718659803513053" LOG_EFFECT_SIZE="1.041392685158225" MODIFIED="2010-05-10 15:13:46 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.4550952040282188" STUDY_ID="STD-Poyurovsky-2006" TOTAL_1="30" TOTAL_2="30" VAR="2.1173020527859236" WEIGHT="6.240938354820727"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-05-11 15:21:01 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-05-11 15:21:01 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASkAAAH4CAIAAACZmYxfAAAVfUlEQVR42u3du64dSRnF8SNNQuBg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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-05-11 15:21:01 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-02-01 05:12:12 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2010-01-13 03:04:02 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-01-12 13:10:35 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-01-12 13:10:35 +0000" MODIFIED_BY="[Empty name]">Search strategy used for previous version of this review (2001)</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-12 13:10:35 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Search methods for identification of studies  </HEADING>
<P>1. Electronic searching<BR/>Relevant randomised trials were identified by searching several electronic databases (Biological Abstracts, The Cochrane Library, Cochrane Schizophrenia Group's Registers of trials (including Big Comp and New Dat databases), EMBASE, LILACS, MEDLINE, and PsycLIT).</P>
<P>1.1. BIOLOGICAL ABSTRACTS (January 1982 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.2 CENTRAL of The Cochrane Library, Issue 3, 2000 was searched using CGS's phrase for schizophrenia and the phrase:</P>
<P>and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)</P>
<P>1.3 COCHRANE SCHIZOPHRENIA GROUP'S REGISTER (November 2000), Big Comp and New Dat were searched using the phrase:</P>
<P>[and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol or #42 = (10 or 18 or 323 or 373 or 374 or 425))]</P>
<P>(#42 is the 'intervention' field of the Register's workform and the numbers are codes for the beta-blocker group of drugs.)</P>
<P>1.4 EMBASE (January 1980 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (adrenergic beta-antagonists exploded or acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.5 LILACS (January 1982 to October 1996) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.6 MEDLINE (January 1966 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (adrenergic beta-antagonists exploded or acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.7 PsycLIT (January 1974 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (adrenergic beta-antagonists exploded or acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>2. Reference searching<BR/>The references of all identified studies were also inspected for more studies.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-01-13 03:04:02 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-01-13 03:04:02 +0000" MODIFIED_BY="[Empty name]">Methods used in previous version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-12 16:41:02 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Methods  </HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Criteria for considering studies for this review  </HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of studies  </HEADING>
<P>All relevant randomised controlled trials lasting over one week.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of participants  </HEADING>
<P>People with schizophrenia, diagnosed by any criteria. Trials were subdivided into those dealing with people with illnesses that had been labeled as 'resistant to antipsychotic drug treatments' and studies that did not have this as an entry criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of interventions  </HEADING>
<P>1. Any beta-blocking drug in conjunction with any antipsychotic drug treatment.<BR/>2. Placebo added to any antipsychotic drug treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of outcome measures  </HEADING>
<P>The principal outcomes of interest were: (i) death; (ii) acceptability of treatment as measured by leaving the study early; and (iii) clinically meaningful changes in mental state, behaviour, and well-being.</P>
<P>Since it has been claimed that beta-blockers are effective in reducing aggression and assaultive behaviour in psychiatric patients, rating scales measuring aggression/assaultive behaviour were recorded when available.</P>
<P>Data were sought relating to the most serious adverse effects of beta-blockers: (i) acute heart failure; (ii) collapse; (iii) severe cardiac arrhythmias; and (iv) acute bronchoconstriction. Reviewers also extracted data on haematological disorders, decrease of libido, and extrapyramidal side effects. Other outcomes recorded in the studies, were, where possible, displayed.</P>
<P>All outcomes were grouped by time - short term (up to 12 weeks), medium term (13 to 26 weeks ) and long term (more than 26 weeks).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Search methods for identification of studies  </HEADING>
<P>1. Electronic searching<BR/>Relevant randomised trials were identified by searching several electronic databases (Biological Abstracts, The Cochrane Library, Cochrane Schizophrenia Group's Registers of trials (including Big Comp and New Dat databases), EMBASE, LILACS, MEDLINE, and PsycLIT).</P>
<P>1.1. BIOLOGICAL ABSTRACTS (January 1982 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.2 CENTRAL of The Cochrane Library, Issue 3, 2000 was searched using CGS's phrase for schizophrenia and the phrase:</P>
<P>and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)</P>
<P>1.3 COCHRANE SCHIZOPHRENIA GROUP'S REGISTER (November 2000), Big Comp and New Dat were searched using the phrase:</P>
<P>[and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol or #42 = (10 or 18 or 323 or 373 or 374 or 425))]</P>
<P>(#42 is the 'intervention' field of the Register's workform and the numbers are codes for the beta-blocker group of drugs.)</P>
<P>1.4 EMBASE (January 1980 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (adrenergic beta-antagonists exploded or acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.5 LILACS (January 1982 to October 1996) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.6 MEDLINE (January 1966 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (adrenergic beta-antagonists exploded or acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>1.7 PsycLIT (January 1974 to November 2000) was searched using the CSG's phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[and (adrenergic beta-antagonists exploded or acebutolol or alprenolol or atenolol or betaxolol or bisoprolol or bupranolol or cartelolol or carvedilol or celiprolol or epanolol or labetalol or metoprolol or nadolol or oxprenolol or pindolol or propranolol or sotalol or timolol)]</P>
<P>2. Reference searching<BR/>The references of all identified studies were also inspected for more studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data collection and analysis  </HEADING>
<P>1. Study selection<BR/>Two reviewers independently inspected all citations identified by the searches, and full reports of the studies of agreed relevance were obtained. Where disputes arose, the full report was also acquired for more detailed scrutiny. Two reviewers then independently inspected all of these full reports. Where it was not possible to resolve disagreement by discussion, the authors of the study were contacted for clarification.</P>
<P>2. Quality assessment<BR/>The reviewers also evaluated the quality of all included trials - again independently of one another. A rating was given for each trial based upon the three quality categories as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>). Only trials in category A or B were included in this review.</P>
<P>3. Data extraction<BR/>No individual data were sought at this stage of the review. JA, MC, and KW again working independently, extracted data, discussed any disagreements, documented decisions and, where necessary, contacted authors of studies to help resolve issues.</P>
<P>4. Data synthesis<BR/>Outcomes are measured using continuous (for example, average changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale - that is 'little change', 'moderate change' or 'much change') or dichotomous forms (for example, either 'no important changes' or 'important changes' in a person's behaviour).</P>
<P>4.1 Dichotomous data: efforts were made to convert all outcome measures to dichotomous data, for example by identifying cut-off points on rating scales and dividing subjects accordingly into 'clinically improved' or 'not clinically improved'. An odds ratio (OR) with 95% confidence interval (CI) was then estimated. The number needed to treat statistic (NNT) was also calculated. Where people were lost to follow-up at the end of the study it was assumed that they had had a poor outcome (with the exception of death) and once they were randomised they were included in the analysis - intention-to-treat analysis.</P>
<P>4.2 Continuous data: continuous data were excluded if more than 50% of people were lost to follow-up. Continuous data were reported as presented in the original studies, without making any assumptions about those lost to follow-up. Weighted mean differences (WMD) were calculated for continuous data.</P>
<P>A wide range of instruments is available to measure outcomes in mental health studies. These instruments vary in quality and many are non-validated, or even ad hoc. It is generally accepted that measuring instruments should have the properties of reliability (the extent to which a test effectively measures anything at all) and validity (the extent to which a test measures that which it is supposed to measure) (<LINK REF="REF-Rust-1989" TYPE="REFERENCE">Rust 1989</LINK>). Before publication of an instrument, most scientific journals insist that reliability and validity be demonstrated to the satisfaction of referees. It was therefore decided, as a minimum standard, not to include any data from an instrument in this review unless the instrument and its properties had been published in a peer-reviewed journal. In addition the following minimum standards for instruments were set: (i) the instrument should either be (a) a self-report, or (b) completed by an independent rater or relative (not the therapist); and (ii) the instrument should be a global assessment of an area of functioning.</P>
<P>Data on mental health outcomes are often not 'normally' distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to all data before inclusion: (i) standard deviations and means were reported in the paper or were obtainable from the authors; and (ii) when a scale starts from a finite number (such as zero), the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Data that did not meet the first or second standard were not entered on the RevMan MetaView software (which assumes a normal distribution). However, data not meeting these standards were reported in the 'Other data' section of the results.</P>
<P>5. Test for heterogeneity<BR/>As well as inspecting the graphical presentations, the reviewers checked whether the differences among the results of trials were greater than would be expected by chance alone using chi squared tests.</P>
<P>6. Sensitivity analysis<BR/>Three sensitivity analyses were planned for this review. The first investigated whether trials using rigorous diagnostic criteria systematically differed in their results from trials using more pragmatic entry criteria. The second examined whether our decision to perform an intention-to-treat analysis affected the final results of the review compared to an analysis using data just from those who completed the studies. Lastly studies where the participants had illnesses that were 'resistant to treatment' were analysed separately to see if this group has a differential response to beta-blockers when compared to those who do not have this label. However, due to lack of data none of the sensitivity analyses were performed.</P>
<P>In all cases the data were entered into RevMan in such a way that the area to the left of the line of no effect indicates a favourable outcome for beta-blockers.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-02-01 05:12:12 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>